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ABSTRACT
Objective: Individuals with Attention-Deficit Hyperactivity Disorder (ADHD) are
attending college at higher rates than ever before. While much research has been performed
to assess academic and vocational outcomes, very few studies have examined quality of
life (QoL) outcomes. The present study sought to closely examine the role of treatment,
executive functioning, symptom severity, and demographic factors in predicting quality of
life among college students with ADHD. Method: Data for the proposed study was gathered through the four year, longitudinal Trajectories Related to ADHD in College Students
(TRAC) project and were analyzed to identify differences in quality of life among college
students with ADHD according to treatment status, executive functioning, ADHD symptom severity, race, ethnicity, and sex. Predictors were compared across individuals with
and without ADHD. Results: Predictors for individuals with and without ADHD were
comparable, with no significant differences within the variables explored. Medication, but
not therapy, was predictive of QoL in Year 1, while executive functioning was predictive
of QoL in Years 1 and 4. Conclusion: Medication and executive functioning emerged as
the most important contributors to QoL in the present model and should be considered in
treatment approaches for college students with ADHD.
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PREFACE
The present thesis has been formatted according to the manuscript guidelines of the
Journal of Attention Disorders, which follows American Psychological Association (APA)
guidelines for formatting and publication. Manuscript format is in use.
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Introduction
Attention-Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder affecting 3-10% of children and adolescents, characterized by developmentally inappropriate attentional deficits, hyperactivity, and impulsivity (American Psychiatric Association, 2013). Despite the academic and social challenges faced by individuals with
ADHD, the pursuance of higher education by this population has increased substantially in
the past two decades. For example, DuPaul and colleagues (2009) reported that 2-8% of all
college students endorse an ADHD diagnosis and 25% of college students with a disability
are diagnosed with ADHD. In fact, ADHD currently represents the fastest-growing disability category among college students (Nelson & Liebel, 2018). As a result of increased
participation in higher education by students with ADHD, there has been a recent increase
in research regarding ADHD in college students. Many of these studies center on the impact of ADHD on academic performance (e.g., Abikoff et al., 2013; Baweja et al., 2015;
Gormley et al., 2019; Jangmo et al., 2019). Although a significant focus has been placed
on the academic performance of college students with ADHD, other domains of functioning have been relatively unexplored. Specifically, issues pertaining to quality of life (QoL),
defined by the World Health Organization as an individual’s subjective judgment of their
life according to their own system of values (WHO Quality of Life, 1995), are relatively
unexplored, even as it has been demonstrated that QoL is adversely impacted by ADHD
(Adler et al., 2013; Coghill, 2010; Klassen et al., 2004; Pinho et al., 2019). Prior research
has demonstrated that there is a significant main effect of ADHD status on QoL (F(1, 356)
= 9.453, p = .002) among college students, as students with ADHD endorse a lower QoL

2

than their peers without ADHD (Pinho et al. 2019). QoL is a multifaceted domain encompassing physical health, psychological health, social interactions, and environmental factors (WHOQOL Group, 1998). Research is needed to compare QoL outcomes between
college students with and without ADHD, to identify whether particular mechanisms of
treatment, such as medication and therapy, are associated with greater improvement in
QoL, and to examine the impact of ADHD considering potential within-group heterogeneity based on demographic and individual factors (Galloway et al., 2019).
Treatment Modalities
Understanding the association between treatment and QoL outcomes among college students with ADHD is crucial, as research has demonstrated both that QoL is significantly impaired in college students with ADHD when compared to students without
ADHD, and that more individuals with ADHD are entering college than have ever before
(DuPaul et al., 2009; Nelson & Liebel, 2018; Pinho et al., 2019). Specifically, a greater
understanding of the role of broad treatment modalities (i.e., medication and therapy) as
they pertain to QoL in college students with ADHD may help to elucidate whether a particular approach would help maximize QoL for college students with this disorder.,
Medication
Stimulant medication is the first line of treatment for ADHD in childhood and adulthood (Shier et al., 2012). The most commonly prescribed stimulant medication for ADHD
across the lifespan, methylphenidate, is effective at reducing ADHD symptoms by up to
31% (Chan et al., 2016; Krinzinger et al., 2019). Nonstimulant medications (e.g., atomoxetine) are also effective in reducing symptoms of ADHD among children and adolescents
(Banaschewski, et al., 2004; Wolraich et al., 2019), although these medications generally
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demonstrate smaller effect sizes than treatment with stimulant medication (e.g., d = .30.69; Chan et al., 2016; Wolraich et al., 2019).
Although prior research has consistently demonstrated that medication is effective
in reducing general symptoms of ADHD (Chan et al., 2016; Corbisiero et al., 2018), specific issues related to QoL outcomes are largely unexplored in the study of treatment’s
efficacy. Within the limited research on this facet of ADHD treatment outcomes, preliminary evidence suggests that medication significantly improves QoL (Temizsoy et al.,
2019). It is important to note that even when medication is associated with enhancement
within this domain, QoL remains below that demonstrated by neurotypical counterparts
(Rajeh et al., 2017). The improvements demonstrated in QoL because of stimulant medication are directly related to improvements in general functioning, with psychosocial domains of QoL improving along with core ADHD symptoms (Coghill, 2010; Danckaerts et
al., 2010). Interestingly, physical QoL, or the sense of physical wellbeing an individual
experiences in the body, has been demonstrated to remain unimproved during treatment of
ADHD with medication (Danckaerts et al., 2010; WHOQOL Group, 1998; Yang et al.,
2007).
The finding that physical QoL remains unaltered after treatment with medication
suggests that the physiological side effects of medication may play a role in QoL. Despite
improvements in symptomology, stimulant medications produce side effects that may substantially interfere with an individual’s daily functioning, including appetite suppression,
insomnia, irritability, anxiety, perceived lower levels of creativity, changed perception of
oneself, depression, psychotic-like symptoms, substance use disorders, tics and dyskinesias, seizures or EEG abnormalities, and aggression (Corbisiero et al., 2018; Krinzinger et
4

al., 2018; Rajeh et al., 2017). However, it should be noted that DuPaul and colleagues
(2012) explored the effectiveness of lisdexamfetamine dimesylate among college students
with ADHD and found that students reported minimal side effects as well as substantial
improvement in executive functioning and psychosocial functioning (DuPaul et al., 2012).
Nonstimulant medication is associated with similar side effects, including somnolence,
gastrointestinal problems, and decreased appetite (Spencer et al., 2007). Less commonly,
atomoxetine is related to hepatitis and growth delays, as well as suicidal thoughts, precipitating an FDA Black Box warning (Bangs et al., 2008; Reed et al., 2016). Several forms
of nonstimulant medication are associated with cardiovascular changes, with atomoxetine
associated with increased heart rate and blood pressure and others associated with decreased heart rate and blood pressure (Vaughan & Kratochvil, 2012). These potentially
severe side effects are important to consider alongside the benefits of medication in other
domains of functioning in order to truly evaluate the role of medication in QoL.
Psychosocial Treatment
Several nonpharmacological, psychosocial techniques are commonly implemented
to improve overall symptoms of ADHD, including contingency management, modified
cognitive behavioral therapy (CBT), and specific skills training (Antshel & Olszewski,
2014; Evans et al., 2014; Evans et al., 2018). Such techniques are beneficial in long-term
functioning because they add a behavioral component to assist with applied tasks related
to academic performance and daily functioning (Corbisiero et al., 2018). The advantage of
the applied focus of psychosocial treatment is seen in the benefits that often persist even
after treatment is ceased, whereas the cessation of medication yields an immediate cessation of benefits (Corbisiero et al., 2018; Wolraich et al., 2019).
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Research supports that psychosocial treatment of ADHD is, in general, associated
with increased QoL, although these results tend to have smaller effect sizes than those
examining the impact of medication (Lopez et al., 2018). While some studies (e.g., Kousha
& Abbasi Kakrodi, 2019) have found that QoL improves in psychological, social, and environmental, but not physical QoL, following psychosocial interventions, other research
demonstrates that these interventions, especially CBT, are associated with improvements
in all domains of QoL, including the physical domain related to fatigue, dependence on
medication, and feelings of energy and restlessness. Pan and colleagues (2019) found that
participants with ADHD receiving an adjusted form of CBT without medication reported
higher physical QoL (b = 8.62, p < 0.01) than those receiving medication alone or a combination of CBT and medication. The comparison of CBT to medication is pertinent, as
stimulant medication has been demonstrated to consistently improve psychosocial, but not
physical, QoL in individuals with ADHD (Danckaerts et al., 2010). Additional research is
needed, however, to explore the magnitude of the relationship between psychosocial treatment and QoL, as preliminary studies demonstrate promising results for increasing QoL.
Combined Approach to Treatment
Given that both medication and psychosocial approaches to improving QoL in individuals with ADHD can be beneficial, providers sometimes turn to a combination of the
two modalities to enhance the benefits of each method of treatment. Indeed, a combined
approach to treatment is recommended by the American Academy of Pediatrics (Wolraich
et al., 2011). Data concerning the benefits of combined treatment, however, are inconsistent
across studies. In some cases, a combined approach has been demonstrated to yield a
greater improvement in symptoms than either approach alone (Rosch et al., 2016; Sprich
et al., 2016). For example, Rosch and colleagues (2016) found that a combined approach
6

can statistically improve executive functioning abilities beyond the level of improvement
demonstrated by one approach alone. Other studies, such as the Multimodal Treatment
Study of Children with ADHD (MTA), however, found that combination treatments do not
offer significantly greater benefits than medication management for ADHD symptoms
among children (Molina et al., 2009). Still, other research has found that a combined approach yields significantly worse outcomes among adults than either modality alone (Pan
et al., 2019).
Examination of a combined approach to treatment among college students with
ADHD is necessary, as much of the research on ADHD treatment is focused on young
children, adolescents, and adults, with little emphasis on emerging adulthood (e.g., Molina
et al., 2009; Pan et al., 2019; Rosch et al., 2016). As a result of the unique academic and
social demands faced by college students, this population may demonstrate different needs
that may be better addressed by a combination of medication and psychosocial treatment.
In particular, study is needed to assess whether treatment in childhood is related to outcomes in early adulthood.
Potential Moderators of the Relationship between Treatment and QoL
In examining QoL among college students with ADHD, it is important to address
potential moderators that may place certain populations at higher risk for negative outcomes. The study of moderators is particularly important as previous studies have demonstrated that treatment is not related to increased global QoL among individuals with ADHD
(Pinho et al., 2019), but has not considered within-group heterogeneity, including variables
such as executive function, symptom severity, and demographic differences. Examining
differences as moderators in the relationship between QoL and treatment modality may
clarify the true outcomes related to treatment.
7

Severity of Symptoms and Executive Functioning Deficits
Severity of ADHD symptoms is important to understand treatment effectiveness in
the domain of QoL. Treatment, particularly medication, has been found to have greater
efficacy when symptoms are more severe (Ginsberg et al., 2011). Individuals with more
severe ADHD symptomology receiving treatment may gain the greatest benefits relative
to their initial QoL endorsement, supporting a stronger relationship between treatment and
QoL among this group. Further, research has found that each core symptom of ADHD
(hyperactivity, impulsivity, inattention) is related to marked deficits across multiple domains of everyday functioning such as managing personal responsibilities, social interactions, and even driving (Weiss et al., 2012). It follows logically that, due to the broad impact of each symptom of ADHD, increased severity of symptoms is likely related to worsened QoL beyond the categorical presence or absence of a diagnosis, with worsened symptoms indicating an exponential impact on QoL (Thorell et al., 2019).
Beyond the core symptoms of ADHD, executive functioning as a distinct subdomain has been found to contribute significantly to QoL. Executive functioning, generally
defined as the cognitive ability to plan, inhibit, regulate, and shift behavior (de Frias, et al.,
2006; Weyandt, 2009), has been shown to account for more variation in QoL than overall
severity of ADHD symptoms (Thorell et al., 2019). Similar to the wide-reaching impact of
ADHD core symptomology, executive functioning is also necessary for the implementation of a broad range of crucial everyday tasks (Barkley & Murphy 2010; Brown & Landgraf, 2010; Dijkhuis et al., 2017; Sanz et al., 2018; Weyandt et al., 2017). Because increased executive functioning abilities are a significant predictor of greater QoL, it is also
important to examine the role of executive functioning as a moderator in the relationship
between treatment and QoL in college students.
8

Demographic Moderators
Race and ethnicity are two variables that have frequently been neglected in ADHD
research, which is particularly concerning given the poor quality of treatment for ADHD
among minoritized groups (Alsalamah, 2018). For example, Black and Hispanic youth with
ADHD receive follow-up care and utilize treatment services at significantly lower rates
than other groups, especially White and non-Hispanic youth (Bailey & Owens, 2005).
Black youth with ADHD are 22.4% more likely to cease medication use and 13.1% more
likely to stop psychosocial treatment than White youth, while Hispanic youth with ADHD
are 16.7% more likely to cease medication use and 9.4% more likely to stop psychosocial
treatment than non-Hispanic youth (Cummings et al., 2017).
Similarly, disparities in outcomes relating to QoL are seen across sexes. Female
children with ADHD experience increased internalizing and somatic symptoms compared
to their male counterparts and are more likely to demonstrate a lower QoL (Dallos et al.,
2017; Skogli et al., 2013; Rucklidge & Tannock, 2001). Specifically, female children with
ADHD have demonstrated heightened impairments in satisfaction with self (Wehmeier et
al., 2012) and stimulant medication is associated with improved QoL in both males and
females. Notably, larger differences are typically found in females, particularly in the domains of restricted activity and comfort. To understand and improve outcomes related to
ADHD across race, ethnicity, and sex, research would benefit from prioritizing issues related to disparities in access and efficacy of treatment in these historically marginalized
and underrepresented groups. Research is needed to determine whether the disparities seen
in childhood continue into young adulthood.
Aims
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A growing presence of students with ADHD in higher education has emerged in
the last two decades, inspiring increased research regarding ADHD symptomology and
academic functioning (DuPaul et al., 2009; Weyandt & DuPaul, 2013). Relatively less attention, however, has been placed on QoL, a critical avenue of study because it relates to
one’s perceived worth in daily functioning (WHO Quality of Life, 1995). Preliminary studies support that ADHD is related to diminished QoL (Adler et al., 2013; Coghill, 2010;
Klassen et al., 2004; Pinho et al., 2019), however, research is lacking regarding the relationship between treatment modality and QoL and whether this relationship is influenced
by within-group heterogeneity. Further, both medication and psychosocial treatments have
been demonstrated as effective in reducing symptoms of ADHD in children and adults,
however, it is unclear whether these treatments have a significant relationship with QoL in
college students (Corbisiero et al., 2018; Krinzinger et al., 2018; Rajeh et al., 2017).
Given the importance of QoL in understanding the full impact of ADHD on the
lives of college students, the purpose of the present study was to closely examine the relationship between various treatment modalities and QoL in college students with ADHD
with particular attention to moderating variables. Based on extant literature, the following
hypotheses were advanced: 1) In a regression model in which race, ethnicity, sex, and executive functioning would be predictive of QoL across the entire sample including college students with and without ADHD, the four regression variables would account for
greater variation in QoL among college students with ADHD compared to college students without ADHD; 2) Reports of a history of psychosocial treatment of ADHD in
Year 1, reports of a history of use of medication for ADHD in Year 1, ADHD symptom
severity, executive functioning ability, race, ethnicity, and sex would create a regression
10

model predictive of QoL among college students with ADHD in Years 1 and 4; 3) Specifically, within the latter model, there would be an interaction between a history of psychosocial treatment and medication indicative of greater QoL in Years 1 and 4; 4) The relationship between treatment in Year 1 and QoL in Years 1 and 4, as explored through regression analyses between treatment and QoL, would be moderated by ADHD symptom
severity and executive functioning ability; 5) The relationship between treatment in Year
1 and QoL in Years 1 and 4 would be moderated by race and ethnicity, with Black and
Hispanic students who reported a history of treatment in Year 1 demonstrating lower
QoL in Years 1 and 4 than White and non-Hispanic students who report a history of treatment in Year 1; 6) The relationship between treatment in Year 1 and QoL in Years 1 and
4 would be moderated by sex, with female participants who report a history of treatment
in Year 1 demonstrating lower QoL in Years 1 and 4 than male participants who report a
history of treatment in Year 1.
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Methods
Procedure
Study procedures were approved by the institutional review board for each data
collection site (University of Rhode Island IRB Number: HU1112-087). Data for the proposed study was gathered through the Trajectories Related to ADHD in College Students
(TRAC) project examining multiple functional trajectories, including behavioral, educational, social, and vocational domains, across early adulthood to identify risk and protective
factors to inform clinical assessment and treatment. Collection of data occurred at three
primary sites, two in the northeast and one in the southeast United States. Six colleges and
universities near the primary sites served as recruitment, but not testing, sites. Two cohorts
of first-year students were recruited across the first year of the project, with a total of n =
219 participants recruited in Cohort 1 and n = 237 participants recruited in Cohort 2. All
participants underwent an annual four-stage assessment with an incentive of up to $100 for
completing all required processes. See Appendix B for descriptions of measures used and
Appendices C-H for copies of the measures used.
Participants were recruited from a variety of sources, including summer orientation
presentations, disability services, student counseling centers, flyers, and presentations to
large, first-year classrooms. Recruited participants were first-year college students between
the ages of 18-25 with and without ADHD. Written consent was obtained before they were
asked to complete current and childhood self-reports of the ADHD Rating Scale (ADHDRS). Participants’ parents were then asked to complete the parent version of the ADHDRS to address current and childhood symptoms of the participant. The data collected by
the self- and parent-report of the ADHD-RS served as the basis of decisions regarding
which participants were excluded from the study and which moved to the next phase of
12

assessment. Participants whose ADHD-RS score indicated possible inclusion underwent
additional evaluation by the Semi-Structured Interview for Adult ADHD and the Structured
Clinical Interview for DSM-5 (SCID-5), which informed decisions pertaining to which
cases were brought to the expert panel for review and final determination of ADHD or
Comparison group classification, as well as psychiatric comorbidity status. To be eligible
for the study, participants either met a full DSM-5 diagnosis for ADHD by demonstrating
five or more symptoms of inattention or hyperactivity, or they met criteria for the Comparison group by demonstrating three or fewer symptoms of inattention or hyperactivity characterized by ADHD, both during childhood and in the past six months. The expert panel
was comprised of four doctoral-level licensed psychologists with expertise and clinical experience with ADHD. Group assignment required unanimous agreement by the panel.
Participants
The Trajectories Related to ADHD in College Students (TRAC) project database
was used for the present study. This longitudinal study followed two cohorts of college
students with and without ADHD from nine different universities in the eastern United
States across four years, beginning in the academic year of 2012-2013. Attrition was evident, with somewhat smaller sample sizes in Year 2 (N = 449, nADHD = 222), Year 3 (N =
452, nADHD = 227), and Year 4 (N = 435, nADHD = 218). Power analyses revealed that the
sample size throughout all four years of data collection was sufficient to detect a medium
effect size across all proposed for a power of .80. Table 1 illustrates the demographic characteristics of the current sample. Participant demographics and characteristics can be seen
in can be found in Tables 1A-F.
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Results
Foundational Analyses
Prior to testing the hypotheses, foundational statistics were completed to test for
multicollinearity. First, the correlation matrix between the subscale scores and global score
of the AIM demonstrated that, as expected, the correlations among each subscale score and
between the global and subscale scores were between .30 < r <.80.
Because the correlation matrices yielded correlations between .30 < r <.80, a multivariate analysis of variance (MANOVA) procedure was performed between the grouping
variable of history of any form of treatment, dichotomized as any treatment and no treatment, and each subscale score of the AIM. The MANOVA was significant (F(6, 210)=
2.45, p = .026. η2 = .065) and revealed that only the “Living with ADHD” subscale was
significantly related to treatment (F(1, 215)= 13.099, p <.001, η2 = .057), hence, only the
“Living with ADHD” subscale was used in future analyses. Results of the correlation matrix and MANOVA can be seen in Tables 2 and 3.
Hypotheses
Hypothesis 1
Hypothesis 1, that race, ethnicity, sex, and executive functioning would be predictive of QoL across the entire sample including college students with and without ADHD,
and more predictive of QoL among participants with ADHD, was tested via two hierarchical multiple regression analyses. The first hierarchical multiple regression analysis was
performed with the dependent variable of global AIM score from Year 2 and the second
was performed with the dependent variable of global AIM score from Year 4. It is important to note that the global AIM scores were only available for the Comparison groups
for Years 2-4, and subscale scores were not available at any time point for the Comparison
14

group. In both analyses, race, ethnicity, and sex were entered as independent variables of
the first hierarchical model and executive functioning, as measured by the Behavior Rating
Inventory of Executive Functioning (BRIEF), was entered as the independent variable in
the second hierarchical model. A visual representation of the hierarchical model can be
found in Figure 1.
The first step of the hierarchical models from Year 2 (nADHD = 180, nComparison =
207), containing only demographic variables, were not significant (ADHD: F(6, 163) =
.680, p = .666; Comparison: F(6,200) = .740, p = .618). When executive functioning was
added to the model, however, significance was achieved for both the ADHD (F(7, 172) =
4.830, p < .001) and Comparison (F(7, 199) = 4.978, p < .001) groups. The addition of
executive functioning to the hierarchical model yielded an increase in the amount of variance accounted from 2.3% to 16.4% in the ADHD group and from 2.2% to 14.9% in the
Comparison group. Executive functioning emerged as the only significant predictor of QoL
within the model (ADHD: ß = -.387, p < .001, Comparison: ß = -.360, p <.001). These
results indicate that greater baseline executive functioning is predictive of QoL, while other
demographic factors were not predictive of QoL in this sample. Further, findings suggest
that executive functioning demographic characteristics account for similar variation in QoL
in college students with and without ADHD. The results of these analyses can be seen in
Tables 4A-D.
The next hierarchical multiple regression analysis contained the same independent
variables as the first regression (i.e., race, ethnicity, and sex added first and executive functioning, as measured by the Behavior Rating Inventory of Executive Functioning (BRIEF)
from Year 2 added second) and the dependent variable of global AIM score in Year 4
15

(nADHD = 74; nComparison = 99). The first hierarchical model containing only demographic
variables as predictors was not significant (ADHD: F(5,68) = .413, p = .838; Comparison:
F(6,92) = .796, p = .575). When executive functioning was added to the analysis, the models remained nonsignificant (ADHD: F(6,67) = 1.414, p = .222; Comparison: F(7,91) =
1.327, p = .247), however the increase in F value following the addition was significant
(pADHD = .015; pComparison = .040). Further, executive functioning emerged as a significant
predictor within the nonsignificant overall model (ADHD: ß = -.305, p = .015, Comparison:
ß = -.210, p = .040). This result indicates that, while the overall hierarchical regression did
not predict QoL in Year 4, executive function continues to be predictive of QoL (See Tables 4E-H).
Hypothesis 2
Hypothesis 2, that reports of a history of psychosocial treatment of ADHD in Year
1, reports of a history of use of medication for ADHD in Year 1, ADHD symptom severity,
executive functioning ability, race, ethnicity, and sex predict QoL among college students
with ADHD in Years 1 and 4, was tested via two separate hierarchical multiple regression
analyses including only data from the ADHD group. The first hierarchical multiple regression first entered demographic variables (i.e., race, ethnicity, and sex), then ADHD symptom severity Year 1 as measured by the Conners’ Adult ADHD Rating Scales (CAARS)
and executive functioning ability in Year as measured by the BRIEF, and finally a history
of treatment as independent variables. The dependent variable for the first hierarchical
multiple regression analysis was the AIM “Living with ADHD” score from Year 1 and the
dependent variable for the second analysis was the AIM “Living with ADHD” score from
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Year 4. The “Living with ADHD” subscale of the AIM, as the MANOVA procedure performed previously demonstrated that this subscale was the only subscale significantly related to treatment. A visual representation of this model can be found in Figure 2. The
sample size of this regression was n = 203 with no evidence of multicollinearity. The second multiple regression included the same predictor variables as the first regression with
the outcome variable of “Living with ADHD” score from Year 4. The sample size of this
regression was n = 75, with no evidence of multicollinearity.
In the first analysis, upon entering the demographic variables, the model was not
significant (F(6, 196) = .407, p = .874). When executive functioning and ADHD symptom
severity were added to the model, it became significant (F(8, 194) = 3.784, p < .001), with
the amount of variance accounted for increasing from 1.2% to 13.5% and the F value increasing significantly (p < .001). Within the model, however, only executive functioning
emerged as a significant predictor of QoL (ß = -.361, p < .001). When treatment was added
to the model, the F value again increased significantly (p < .001) and the amount of variance accounted for increased from 13.5% to 19.1%. The overall model was also significant
(F(9, 193) = 5.065, p < .001). To further investigate the impact of treatment, the treatment
variable was parsed into medication only and therapy only and added to the model. With
the addition of medication alone, the F value increased significantly (p = .003) and the
amount of variance accounted for increased from 19.1% to 22.7%. The addition of therapy
only, however, did not yield a significant increase in the F value (p = .074) and only increased the amount of variance accounted for by 1.3%. Medication (ß = .310, p < .001)
emerged as a significant predictor in this final model, while therapy (ß = .153, p = .074)
was not a significant predictor of QoL within the model. These results indicate that, within
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the paradigm of treatment, medication, and not therapy, is predictive of QoL (See Table
5A-5B).
A second analysis containing the same predictors from the previous analysis (i.e.,
demographic variables entered first, executive functioning and ADHD symptom severity
entered second, and reports of a history of treatment subsequently entered) was performed
with the independent variable of AIM “Living with ADHD” from Year 4 (n = 75). The first
model containing only demographic variables was not significant (F(6,68) = .453, p =
.840). The addition of ADHD symptom severity and executive functioning significantly
increased the F value (p = .002) and increased the amount of variance accounted for from
3.8% to 20.5%. The overall model became significant with this addition, as well (F(8, 66)
= 2.125, p = .045). Within this model, however, executive functioning was the only significant predictor (ß = -.473, p < .001). ADHD symptom severity was not significant (ß =
.083, p = .501). The addition of treatment variables (i.e., a history of any treatment, a history of medication, and a history of therapy) in the subsequent three models did not yield
a significant improvement in F value, and the overall model became nonsignificant with
each addition (F(11, 63) = 1.632, p = .112; See Tables 5C and 5D). These results indicate
that executive functioning remains significantly predictive of QoL over the four years of
college, however treatment loses significance over time. It is possible that this lack of significance may be due to decreased power from lower sample size in Year 4 (n = 75.
The results of Hypothesis 2 indicate that medication use and executive functioning
are significant predictors of QoL am).ng college students with ADHD. While a history of
any form of treatment was initially significantly predictive of QoL, when medication was
added to the model, general treatment history lost significance, suggesting that medication
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is the component of treatment relating to improved QoL. Notably, treatment was no longer
significantly predictive of QoL in Year 4, possibly indicating that treatment, in particular
medication, is no longer associated with improvement in QoL over time. It is plausible that
his relationship may be due to the mechanism of treatment (i.e., side effects or tolerance),
loss of power from decreased sample size, or the fact that relationships become weaker
over time. Greater analysis of the roles of medication and therapy, specifically their commencement and cessation, can be found in post-hoc tests 1 and 2 (Appendix A).
Hypothesis 3
Hypothesis 3, that there would be an interaction medication and therapy indicating
that QoL was higher when both modalities were endorsed, was tested using the basic model
(i.e., sex, race, and ethnicity entered first, executive functioning and symptom severity entered second, and the medication/therapy interaction entered third) from Hypothesis 2. The
interaction was significant (ß = .287, p < .001) when it was entered, indicating that a history
of both therapy and medication is indicative of greater QoL than either modality alone.
When medication and therapy were added to the model in an additional step, however, the
interaction was no longer significant. Rather, a history of medication was significantly predictive of QoL (ß = .241, p = .012), while therapy (ß = .089, p =.400) and the interaction
term (ß = .064, p = .633) remained nonsignificant. Executive functioning was a significant
predictor in both models (first: ß = -.487, p < .001; second: ß = -4.966 p < .001) utilizing
the AIM Living with ADHD score from Year 1 (See Tables 6A and 6B).
The same predictors (i.e., demographic variables entered first, executive functioning and ADHD symptom severity entered second, and the medication and therapy interaction entered last) were utilized in a model predicting QoL in Year 4. The overall model was
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nonsignificant with the addition of the interaction term (F(9, 65) = 2.012, p = .052) and the
interaction term itself was not significant(ß = .126, p =.301). When a history of therapy (ß
= .073, p =.732), and history of medication (ß = .105, p =.581) were added, the model
remained nonsignificant (F(11,63) = 1.632, p = .112). Executive functioning was the only
significant predictor in both models utilizing the AIM Living with ADHD score from Year
4 (first: ß = -.362, p < .001; second ß = -.3.587, p < .001; See Tables 6C and 6D).
Similar to the findings from Hypothesis 2, these results indicate that medication,
and not therapy, is a significant predictor of QoL in Year 1. The role of medication in Year
4, however, is diminished and no longer serves as a significant predictor of QoL. These
results suggest that either medication is no longer associated with QoL over time, or
demonstrates that the sample size in Year 4 (n = 75) may be too small to detect the association. Executive functioning remained a significant predictor of QoL regardless of the other
predictors entered into the model in both Year 1 and Year 4.
Hypothesis 4
Hypothesis 4, that the relationship between report of a history of treatment, as measured by the SCSI, and QoL, as measured by the AIM, would be influenced by ADHD
symptom severity, as measured by the CAARS, and executive functioning ability was
tested using analysis of covariance (ANCOVA). Any treatment (i.e., medication and/or
therapy) served as the independent variable and the “Living with ADHD” subscale of the
AIM in Years 1 and 4 served as outcome variables. The covariates of the model were
CAARS and BRIEF scores.
The first ANCOVA conducted, utilizing the “Living with ADHD” (n = 203, ntreatment

= 161) subscale score from Year 1 as a dependent variable, revealed that a significant
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difference in the relationship between a history of treatment and QoL when executive functioning and ADHD symptom severity were taken into account (F(1, 203) = 16.172, p <
.001, ηp = .075). Specifically, the ANCOVA revealed that greater executive functioning
ability and ADHD symptom severity are predictive of a greater correlation between treatment and QoL. The second ANCOVA (n = 75, ntreatment = 65), utilizing the “Living with
ADHD” subscale score of the AIM from Year 4 as the dependent variable did not reveal a
significant difference in the relationship between treatment and QoL when executive functioning and ADHD symptom severity were taken into account (F(1, 74) = .112, p = .738,
η2p = .002). While the overall model was nonsignificant, the contribution of ADHD symptom severity was significant in Year 4 (F(1,71) = 9.618, p = .003). Levene’s test of equality
of error variances was nonsignificant (p = .919), indicating equal variances between groups
(See Tables 7A and 7B).
Next, the ANCOVA for Year 1 was repeated with the treatment variable (i.e., any
treatment) replaced by medication only and again with therapy only (n = 203, nmedication=
127, ntherapy = 120). Results suggested that there was a significant difference in the relationship between a history of medication and QoL when executive functioning and ADHD
symptom severity were taken into account (F(1, 203) = 25.944, p < .001, η2p = .115). These
results suggest that executive functioning ability significantly influences the relationship
between treatment and QoL. Both greater executive functioning and ADHD symptom severity were significant predictors of increased QoL. The relationship between therapy and
QoL was also significantly strengthened by greater executive function (F(1, 204) = 8.574,
p = .004, η2p =.041). Levene’s test of equality of error variances was nonsignificant (p =
.595), indicating equal variances between groups (See Tables 7C and 7D).
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These results support that executive functioning ability is an important consideration in the relationship between treatment and QoL as it appears to strengthen the relationship between QoL and treatment. Again, these results are no longer significant in Year 4,
possibly due to the small sample size and low statistical power. Greater analysis of the role
of executive functioning can be found in post-hoc 3 (Appendix A).
Hypothesis 5
Hypothesis 5, that the relationship between reports of a history of treatment in Year
1, as measured by the SCSI, and QoL, as measured by the AIM, would be influenced by
race and ethnicity, was tested through an ANOVA (n = 218) between the independent variables of race, ethnicity, and history of treatment and the dependent variable of “Living
with ADHD” subscale score of the AIM in Year 1. The ANOVA found that neither race
(F(3, 204) = .958, p = .414, η2p = .014) nor ethnicity (F(1, 204) = .347, p = .347, η2p = .001)
significantly impacted the relationship between treatment and QoL. When utilizing the
“Living with ADHD” score of the AIM from Year 4 (n = 78) the second ANOVA similarly
found that neither race (F(1, 67) = .451, p = .504, η2p = .007) nor ethnicity (F(1, 67) = .030,
p = .863. η2p = .000) significantly impacted the relationship between treatment and QoL
(See Tables 8A and 8B and Figures 3A-D). When race was parsed into White and all other
races in an attempt to improve group sizes and, subsequently, power, race remained nonsignificant in the relationship between treatment and quality of life (F(1,218) = 1.663, p =
.199, η2p = .008).
A chi square test was performed next to explore whether any racial or ethnic group
demonstrated a difference in endorsement of treatment. The chi square test was not significant across race (chi square (4, N = 204) = 6.824, p = .146), indicating that there is no
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difference in endorsement of treatment across race in the current sample. Similarly, according to ethnicity, there was not a significant difference in endorsement of treatment
across groups (chi square (1, N = 228) = 2.061, p = .901), indicating that there is a similar
distribution of endorsement of treatment among Hispanic and non-Hispanic participants
(See Tables 8C-F). Greater analysis of the role of race in treatment can be found in posthoc tests 4 and 5 (Appendix A).
Hypothesis 6
Hypothesis 6, that the relationship between treatment in Year 1 and QoL in Years
1 and 4 would be impacted by sex was explored through a two-way ANOVA (nYear1 = 218,
nYear4 = 78) with the grouping variables of sex and treatment history and the outcome variable of QoL, as measured by the “Living with ADHD” subscale of the AIM. There was
no significant association between sex and the relationship between treatment and QoL in
Year 1 (F(1, 110) = .078, p = .780, η2p = .000) or in Year 4 (F(1, 40) = .983, p = .325, η2p
= .013; See Tables 9A-9B and Figures 4A and 4B).
Last, to further explore the relationship between sex and treatment status, a ChiSquare test was performed to determine whether there is significantly different endorsement of treatment across sexes. The chi square was not significant (chi square (1, N =
228) = 1.789, p = .180), indicating similar endorsement of treatment across sexes (See
Tables 9C and 9D).
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Discussion
The purpose of the present study was to examine the relationship between treatment
(i.e., medication and therapy) and QoL among college students while considering covariates (i.e., executive functioning, ADHD symptom severity, race, ethnicity, and sex) that
might influence this relationship. Overall, executive functioning and medication emerged
as the two most important contributors to QoL in the present models. Greater executive
functioning was significantly predictive of greater QoL regardless of the year of study,
treatment modality (i.e., medication or therapy), or sample (i.e., comparison or ADHD).
This result is consistent with previous studies demonstrating that executive functioning is
critical for academic performance, cognitive ability, and QoL, underscoring the importance
of this executive functioning among college students with and without ADHD (e.g.,
Dijkhuis et al., 2017; Ludwig et al., 2018; Stern et al., 2017). This relationship has also
been demonstrated cross-culturally, with prior research supporting that executive dysfunction significantly reduces QoL among both Hispanic and non-Hispanic individuals (Huang
et al., 2020). Indeed, in the present study, executive functioning emerged as a stronger
predictor of QoL than race or ethnicity. Beyond demographic characteristics, the relationship between executive functioning and QoL remained regardless of ADHD diagnosis status. The literature supports that executive functioning is important across a wide range of
psychological diagnoses, such as bipolar disorder, and physical health concerns, such as
epilepsy and Marfan Syndrome (Cotrena et al., 2016; Ratiu et al., 2018; Sanz et al., 2018;
Schraegle & Titus, 2021). Collectively, these findings support that executive functioning
is a critical component of QoL and suggest that improvements in executive functioning
may improve QoL among heterogeneous samples of college students regardless of culture,
physical and mental health concerns, or neurodevelopmental differences.
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Beyond executive functioning, the paradigm of treatment was considered in relation to QoL. As hypothesized, medication use was significantly predictive of QoL in Year
1. This finding is in line with research by Buitelaar and colleagues (2012) and Banaschewski and colleagues (2014), who found improvements in QoL following 52 weeks of treatment by methylphenidate and 24 months of treatment by lisdexamfetamine dimesylate
(Vyvanse), respectively. While such research supports improvements following medication use for up to two years, the present study found that medication was no longer predictive of QoL in Year 4. Additional studies have found similar results regarding long term
use of stimulant medication. For example, Matthijissen and colleagues (2019) found no
difference in QoL among individuals with ADHD who were or were not taking medication
after two years. These findings suggest that medication treatment effects may wane over
time, which raises issues concerning the age at which medication is begun for maximal
efficacy. Although not addressed by the present study, it may be important for future research to consider whether medication is a sustainable long-term treatment for ADHD
symptomology in college students.
Akin to the findings regarding medication and QoL, a combined approach to treatment (i.e., both therapy and medication) was only significantly predictive of QoL in Year
1. The significance, no longer existed, however, when the medication only variable was
added to the model as a covariate. This finding is supported by research by the MTA Cooperative Group (1999), which suggested that medication, and not therapy or a combined
approach, is the most important contributor to treatment outcomes (i.e., a reduction in
ADHD symptomology). Collectively these findings suggest that medication, rather than
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therapy, is the component of a combined treatment approach that predicts significant improvements in QoL.
The small role that therapy may play in QoL was highlighted with the finding that
therapy alone was not significantly predictive of QoL in any model. This finding contradicts prior research demonstrating that a wide range of behavioral interventions can be
highly effective in treating ADHD (Charach et al., 2013; Fabiano et al., 2009). The results
of the present study are, however, in line with other research supporting that therapy is not
as important in contributing to treatment outcomes as medication. For example, Ackermann and colleagues (2018) demonstrated that medication improves cognitive ability beyond the effect of behavioral intervention. While these results are not specific to QoL,
when paired with the results of the present study, it is supported that medication is critical
across multiple facets of functioning.
Due to the demonstrated importance of medication in improving QoL, it logically
follows that ADHD symptom severity would be significantly associated with QoL. Despite
this, ADHD symptom severity did not directly predict QoL among college students in the
present study. It was, however, a significant covariate in the relationship between treatment
and QoL. Specifically, individuals with more severe ADHD symptomology demonstrated
a stronger relationship between treatment and QoL. This finding contradicts past research
demonstrating that ADHD symptom severity contributes uniquely as a predictor of QoL
(Klassen et al., 2004; Miklós et al., 2019; Thorell et al., 2019). Due to the role of ADHD
symptom severity as a moderator in the relationship between treatment and QoL, however,
it is still an important construct to consider when evaluating QoL among college students
with ADHD.
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In addition to treatment, demographic factors were also explored in their relationship with QoL. Contrary to expectations, the relationship between treatment and QoL was
not significantly moderated by race, ethnicity, or sex. This finding was unexpected due to
several studies finding that demographic factors account for a significant amount of variation in measures of ADHD (DuPaul et al., 2020; Manly et al., 2011) and suggests that
symptoms and outcomes may vary across race, ethnicity, and sex and that treatment should
be specifically tailored to each group. Further, previous research found that Black and Hispanic individuals are more likely to receive worse quality of treatment and lower rates of
follow-up care for ADHD than White and non-Hispanic individuals (Cummings et al.,
2017). Paired with the findings of the present study underlining the importance of treatment
in QoL, these racial and ethnic differences in quality of care suggest that differences would
be seen in the relationship between treatment and QoL according to race and ethnicity. One
possible explanation for the result that demographic characteristics are not related to the
efficacy of treatment in the present study is that a sample of Black and Hispanic college
students does not fully represent the Black and Hispanic young adult population, as there
are significantly fewer Black and Hispanic students in degree-granting college programs
compared to White students (Baker et al., 2018).
While no demographic variables were associated with QoL in the present models,
post-hoc tests revealed that endorsement of medication use differed significantly across
race. Specifically, Black students endorsed medication at significantly lower rates than
White students. Racial disparities in the treatment of ADHD are prominent in the literature,
with Black children endorsing lower rates of treatment than White children (Cocker et al.,
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2016). This finding is particularly important because it underlines the need to increase access to ADHD treatment to improve outcomes among Black students. Unlike race, endorsement of treatment did not differ across sex and ethnicity. This lack of sex difference in
endorsement of treatment is consistent with previous studies finding that females are as
likely to receive medication and therapy as their male counterparts (Mowlem et al., 2019).
Inconsistent with previous research, however, was the finding that endorsement of treatment did not vary across ethnicity. In the current study, Hispanic and non-Hispanic participants were equally likely to endorse prior treatment, contradicting the findings of researchers such as Cocker and colleagues (2016), that suggest that Hispanic children have a lower
likelihood of being treated for ADHD. It is important to note that a possible explanation
for this discrepancy is that the current sample was underpowered to detect a small or medium effect according to ethnicity, with only n = 24 Hispanic participants with ADHD
included. To detect medium effect size in endorsement of treatment, 210 total participants
split evenly into Hispanic and non-Hispanic groups would be needed.
It is important to note that the present study faced several limitations. First, the
sample size from Year 4 (nAIM = 75) was smaller than that of Year 1 (nAIM = 204). The
sample from Year 4 was underpowered to capture a small or medium effect size, possibly
contributing to the nonsignificant results in Year 4. A second limitation is that the Comparison group only completed the AIM in Years 2-4, and only the global score was available, hence comparison of QoL in the first year of college between individuals with and
without ADHD was not possible. Finally, in the current dataset, medication is not parsed
into different types of medication (e.g., stimulant and nonstimulant) and therapy is defined
broadly, with no definition of the specific type of therapy (e.g., CBT, skills training, etc.)
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that was used by participants. In addition, school-based interventions (e.g., IEP, 504 plan,
etc.) were not investigated.
In summation, the findings from the current study emphasize the importance of
executive functioning and medication in predicting increased QoL in college students with
ADHD. Future research would benefit from exploring possible executive functioning interventions to improve QoL broadly among college students. For example, Poissant and
colleagues (2019) found that an intervention targeting both ADHD symptoms and executive functioning was effective in improving QoL among adults with ADHD. Given that
such interventions are preliminarily effective among adults, similar interventions may improve QoL among college students as well. Beyond executive functioning, interventions to
improve medication adherence in college students may also be helpful, as the present study
supports that medication use predicts greater QoL among college students with ADHD.
Cessation of use of medication is common through the transition to college (Edvinsson &
Ekselius, 2018a; Edvinsson & Ekselius, 2018b), and further study is warranted to understand the causes and implications of this cessation, as well as mechanisms to improve medication adherence during this period of development. Finally, a longitudinal experimental
design examining the role of medication in QoL throughout the four years of college is
needed to expand upon the finding of the present study that medication was no longer predictive of QoL in Year 4. Such research would aid in elucidating the importance of medication as a long- or short-term treatment for college students with ADHD.
As larger numbers of students with ADHD are entering college than ever before
(DuPaul et al., 2009; Nelson & Liebel, 2018), it is of paramount importance to understand
the unique profiles of these students. While the academic performance of college students
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with ADHD has been frequently evaluated, QoL is a relatively understudied issue with
wide-reaching implications in the health and wellbeing of these students. The present study
aids in filling this gap in the research by illustrating the unique predictors of QoL in college
students with ADHD (i.e., medication use and executive functioning), helping professionals working with this population understand potentially important contributors to QoL to
improve the likelihood of these students succeeding in college.
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Tables
Table 1A.
Demographic Characteristics of Sample in Year 1 (N = 456)
Characteristics
ADHD
n = 228 (50%)
Ethnicity
Hispanic
24 (10.4%)
non-Hispanic
204 (89.5%)
Race
White
175 (76.8%)
Black
25 (11.0%)
Asian
6 (2.6%)
More than one race
10 (4.4%)
Other
12 (5.3%)
Sex
Male
109 (47.8%)
Female
119 (52.2%)
Mean age (sd)
18.27 (0.58)
Table 1B.
Descriptive Statistics: ADHD and Comparison Groups
ADHD
N
Mean
SD
CAARS DSM Total Score
(Year 1)
228
31.64 8.804
CAARS DSM Total Score
(Year 4)
77
23.1 8.816
ADHD Impact Module: Overall
(Year 2)
184
7.08 1.531
ADHD Impact Module: Overall
(Year 4)
79
7.33 1.517
ADHD Impact Module: Living
with ADHD (Year 1)
218 57.9702 12.868
ADHD Impact Module: Living
with ADHD (Year 4)
78 60.1603 11.377
BRIEF Composite (Year 1)
205 137.95 21.986
BRIEF Composite (Year 2)
182 134.04 26.119
BRIEF Composite (Year 4)
79 130.34 24.583
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Comparison
n = 228 (50%)
23 (10.1%)
205 (89.9%)
152 (66.7%)
31 (13.6%)
19 (8.3%)
8 (3.5%)
18 (7.9%)
111 (48.7%)
117 (51.3%)
18.19 (0.46)

Comparison
N Mean
SD
228

8.89

6.163

100

7.2

6.257

207

7.91

1.312

99

7.92

1.275

NA

NA

NA

NA
216
209
100

NA
NA
93.47 15.439
88.62 18.578
88.53 18.606

Table 1C.
Any Treatment Among College Students with ADHD
Frequency
Percent
No
42
Yes
186
Total
228

18.4
81.6
100

Table 1D.
Medication and Therapy Among College Students with ADHD
Frequency
Percent
No
118
Yes
110
Total
228

51.8
48.2
100

Table 1E.
History of Medication Among College Students with ADHD
Frequency
Percent
No
Yes
Total

77
151
228

33.8
66.2
100

Table 1F.
History of Therapy Among College Students with ADHD
Frequency
Percent
No
83
Yes
145
Total
228

48

36.4
63.6
100

Table 2.
ADHD Impact Module Correlation Matrix (n = 204)

AIM Overall
Score

49

AIM Overall
Score
Living with
ADHD
General Wellbeing
Performance and
Daily Functioning
Relationships
and Communication
Symptom Impact:
Bother/Concern
Symptom Impact: Daily Interference

Living
with
ADHD

General
Wellbeing

Performance and
Daily Functioning

Relationships and
Communication

Symptom Impact:
Bother/Concern

Symptom Impact:
Daily Interference

1
.461**

1

.510**

.604**

1

.396**

.539**

.586**

1

.214**

.199**

.331**

.234**

1

.305**

.414**

.650**

.422**

.326**

1

.359**

.426**

.655**

.465**

.454**

.761**

**correlation is significant at the 0.01 level (2-tailed)

1

Table 3.
ADHD Impact Module MANOVA Results (n = 217)

Living with ADHD
General Wellbeing
Performance and Daily Functioning
Symptoms Impact: Bother/Concern
Symptom Impact: Daily Interference
*Alpha = .05

df Error F
Sig.
1
215 13.099 <.001
1
215 1.669 0.198
1
215 2.885 0.091
1
215 0.922 0.338
1
215 0.478
0.49

Partial
Eta
Squared
0.057
0.008
0.013
0.004
0.002

Table 4A.
Change in Model of Predictors of Quality of Life Among College Students with ADHD
(Year 2)
(n = 180)
R
Std. Error of the
Model
R
Square Estimate
Change Statistics
R Square F
Sig. F
Change
Change df1 df2
Change
Demographics
Executive
Functioning

0.152

0.023

1.517

0.023

0.68

6

173

0.666

0.405

0.164

1.408

0.141

29.066

1

172

<.001

Table 4B.
Overall Model of Predictors of Quality of Life Among College
Students with ADHD (Year 2)
(n = 180)
Model
Demographics

Executive Functioning

df
Regression
Residual
Total
Regression
Residual
Total

F
Sig.
6 0.68
0.666
173
179
7 4.83
<.001
172
179
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Table 4C.
Change in Model of Predictors of Quality of Life Among College Students without ADHD
(Year 2)
(n =207)
R
Std. Error of
Model
R
Square the Estimate Change Statistics
R
Square
F
Sig. F
Change
Change df1 df2
Change
Demographics
Executive
Functioning

0.147

0.022

1.317

0.022

0.74

6

200

0.618

0.386

0.149

1.231

0.127

29.766

1

199

<.001

Table 4D.
Overall Model of Predictors of Quality of Life Among College Students
without ADHD (Year 2)
(n =207)
Model
df
F
Sig.
Demographics
Regression
6 0.74
0.618
Residual
200
Total
206
Executive Functioning
Regression
7 4.978
<.001
Residual
199
Total
206
Table 4E.
Change in Model of Predictors of Quality of Life Among College Students with ADHD (Year
4)
(n = 74)
R
Std. Error of
Model
R
Square the Estimate
Change Statistics
R
Square
Sig. F
Change F Change df1
df2 Change
Demographics
Executive
Functioning

0.172

0.029

1.575

0.029

0.413

5

68

0.838

0.335

0.112

1.518

0.083

6.262

1

67

0.015

51

Table 4F.
Overall Model of Predictors of Quality of Life Among College Students with ADHD
(Year 4)
(n = 74)
Model
df
F
Sig.
Demographics
Regression
5 0.413 0.838
Residual
68
Total
73
Executive Functioning
Regression
6 1.414 0.222
Residual
67
Total
73
Table 4G.
Change in Model of Predictors of Quality of Life Among College Students without ADHD
(Year 4)
(n = 99)
R
Std. Error of
Model
R
Square the Estimate
Change Statistics
R
Square
F
Sig. F
Change Change df1 df2 Change
Demographics
Executive
Functioning

0.222

0.049

1.283

0.049

0.796

6

92

0.575

0.304

0.093

1.261

0.043

4.337

1

91

0.04

Table 4H.
Overall Model of Predictors of Quality of Life Among College Students without ADHD
(Year 4)
(n = 99)
Model
df
F
Sig.
Demographics
Regression
6
0.796
0.575
Residual
92
Total
98
Executive Functioning
Regression
7
1.327
0.247
Residual
91
Total
98
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Table 5A.
Change in Model of Treatment and Quality of Life Among College Students with ADHD
(Year 1)
(n = 203)
R
Std. Error of
Model
R
Square the Estimate
Change Statistics
R
Square F
Sig. F
Change Change df1 df2 Change
Demographics
ADHD Symptom
and Executive
Function

0.111

0.012

12.96918

0.012

0.407

6

196

0.874

0.367

0.135

12.19944

0.123

13.757

2

194

<.001

Any Treatment
Medication

0.437
0.476

0.191
0.227

11.82785
11.59436

0.056
0.036

13.381
8.852

1
1

193
192

<.001
0.003

Therapy

0.489

0.24

11.52763

0.013

3.23

1

191

0.074

Table 5B.
Overall Model of Treatment and Quality of Life Among College Students with ADHD
(Year 1)
(n = 203)
Model
df
F
Sig.
Demographics
Regression
6 0.407 0.874
Residual
196
Total
202
ADHD Symptom and Executive Function
Regression
8 3.784 <.001
Residual
194
Total
202
Any Treatment
Regression
9 5.065 <.001
Residual
193
Total
202
Medication
Regression
10 5.629 <.001
Residual
192
Total
202
Therapy
Regression
11 5.471 <.001
Residual
191
Total
202
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Table 5C.
Change in Model of Treatment and Quality of Life Among College Students with ADHD
(Year 4)
(n = 75)
R
Std. Error of
Model
R
Square the Estimate Change Statistics
R
Square F
Sig. F
Change Change df1 df2 Change
Demographics
ADHD Symptom
and Executive
Function

0.196

0.038

11.559

0.038

0.453

6

68

0.84

0.453

0.205

10.669

0.166

6.906

2

66

0.002

Any Treatment
Medication

0.461
0.465

0.212
0.216

10.701
10.757

0.007
0.004

0.615
0.319

1
1

65
64

0.436
0.574

Therapy

0.471

0.222

10.804

0.006

0.448

1

63

0.506

Table 5D.
Overall Model of Treatment and Quality of Life Among College Students with ADHD
(Year 4)
(n =75)
Model
df
F
Sig.
Demographics
Regression
6 0.453
0.84
Residual
68
Total
74
ADHD Symptom and Executive Function
Regression
8 2.125 0.045
Residual
66
Total
74
Any Treatment
Regression
9 1.946 0.061
Residual
65
Total
74
Medication
Regression
10 1.765 0.085
Residual
64
Total
74
Therapy
Regression
11 1.632 0.112
Residual
63
Total
74
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Table 6A.
Change in Model of Therapy and Medication Interaction (Year 1)
(n = 203)
R
Std. Error of
Model
R
Square the Estimate
Change Statistics
R
Square F
Change Change
Demographics
ADHD Symptom and
Executive Function
Therapy/Medication
Interaction
Therapy and Medication

df1

df2

Sig. F
Change

0.111

0.012

12.969

0.012

0.407

6

196

0.874

0.367

0.135

12.199

0.123

13.757

2

194

<.001

0.462

0.214

11.661

0.079

19.323

1

193

<.001

0.489

0.24

11.528

0.026

3.249

2

191

0.041

Table 6B.
Overall Model of Therapy and Medication Interaction (Year 1)
(n = 203)
Model
df
Demographics

ADHD Symptom Severity and Executive Function

Therapy/Medication Interaction

Therapy and Medication

F

Sig.

Regression
Residual
Total

6
196
202

0.407

0.874

Regression
Residual
Total
Regression
Residual
Total
Regression
Residual
Total

8
194
202
9
193
202
11
191
202

3.784

<.001

5.829

<.001

5.471

<.001
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Table 6C.
Change in Model of Therapy and Medication Interaction (Year 4)
(n = 75)
Model

Demographics
ADHD Symptom
and Executive Function
Therapy/Medication
Interaction
Therapy and Medication

R

R
Square

Std. Error of
the Estimate

Change Statistics
R
Square
Change

F
Change

df1

df2

Sig. F
Change

0.196

0.038

11.559

0.038

0.453

6

68

0.84

0.453

0.205

10.670

0.166

6.906

2

66

0.002

0.467

0.218

10.663

0.013

1.086

1

65

0.301

0.471

0.222

10.804

0.004

0.155

2

63

0.857

Table 6D.
Overall Model of Therapy and Medication Interaction (Year 4)
(n = 75)
Model
Demographics

ADHD Symptom Severity and Executive Function

Therapy/Medication Interaction

Therapy and Medication

df

F

Sig.

Regression
Residual
Total

6
68
74

0.453

Regression
Residual
Total
Regression
Residual
Total
Regression
Residual
Total

8
66
74
9
65
74
11
63
74

2.125 0.045
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0.84

2.012 0.052

1.632 0.112

Table 7A.
Executive Functioning and ADHD Symptom Severity with Any
Treatment (Year 1)
(n = 203)
Partial Eta
Source
df
F
Sig.
Squared
Corrected Model
3
15.256 <.001
0.187
Intercept
1 163.277 <.001
0.451
BRIEF Composite
1
29.946 <.001
0.131
CAARS DSM Total Score
1
4.079 0.045
0.02
Any treatment
1
16.172 <.001
0.075
Error
199
Total
203
Corrected Total
202
Table 7B.
Executive Functioning and ADHD Symptom Severity with Any
Treatment (Year 4)
(n = 75)
Partial Eta
Source
df
F
Sig.
Squared
Corrected Model
3
3.578 0.018
0.131
Intercept
1 99.002 <.001
0.582
BRIEF Composite
1
0.41 0.524
0.006
CAARS DSM Total Score
1
9.618 0.003
0.119
Any treatment
1
0.112 0.738
0.002
Error
71
Total
75
Corrected Total
74
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Table 7C.
Executive Functioning and ADHD Symptom Severity with Medication (Year 1)
(n = 203)
Source
Corrected Model
Intercept
BRIEF Composite
CAARS DSM Total Score
Medication
Error
Total
Corrected Total

df
3
1
1
1
1
199
203
202

F
18.066
243.287
21.733
0.583
25.944

Sig.
<.001
<.001
<.001
0.446
<.001

Partial Eta
Squared
0.214
0.55
0.098
0.003
0.115

Table 7D.
Executive Functioning and ADHD Symptom Severity with Therapy (Year 1)
(n = 203)
Source

df

F

Sig.

Corrected Model
Intercept
BRIEF Composite
CAARS DSM Total Score
Therapy
Error
Total
Corrected Total

3 11.548
1 255.414
1 21.373
1
0.035
1
8.574
199
203
202
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<.001
<.001
<.001
0.851
0.004

Partial Eta
Squared
0.148
0.562
0.097
.000
0.041

Table 8A.
Race and Ethnicity and Quality of Life (Year 1)
(n = 218)
Source
Corrected Model
Intercept
Any treatment
Race
Ethnicity
Treatment Race Interaction
Treatment Ethnicity Interaction
Race Ethnicity Interaction
Error
Total
Corrected Total

df
13
1
1
4
1
3
1
3
204
218
217

F
1.465
665.9
3.618
0.183
1.393
0.958
0.13
0.347

Sig.
0.133
<.001
0.059
0.947
0.239
0.414
0.719
0.792

Partial Eta
Squared
0.085
0.765
0.017
0.004
0.007
0.014
0.001
0.005

Sig.
0.966
<.001
0.721
0.861
0.631
0.504
0.863
0.965

Partial Eta
Squared
0.049
0.843
0.002
0.019
0.003
0.007
.000
0.001

Table 8B.
Race and Ethnicity and Quality of Life (Year 4)
(n = 78)
Source
Corrected Model
Intercept
Any treatment
Race
Ethnicity
Treatment Race Interaction
Treatment Ethnicity Interaction
Race Ethnicity Interaction
Error
Total
Corrected Total

df
10
1
1
4
1
1
1
2
67
78
77

F
0.343
359.56
0.129
0.324
0.233
0.451
0.03
0.036
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Table 8C.
Chi Square Tests: Race and Treatment

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear Association
N of Valid Cases

Asymptotic Significance
Value df (2-sided)
6.824 4
0.146
6.451 4
0.168
1.63 1
0.202
204

Table 8D.
Treatment Counts Across Race

Count

No History of
Treatment
42

History of
Treatment
113

Total
155

% within sample

27.10%

72.90%

100.00%

% within treatment
Adjusted Residual
Count

65.60%
-2.3
13

80.70%
2.3
12

76.00%

% within sample

52.00%

48.00%

100.00%

% within treatment
Adjusted Residual
Count

20.30%
2.4
2

8.60%
-2.4
4

12.30%

% within sample

33.30%

66.70%

100.00%

% within treatment
Adjusted Residual

3.10%
0.1

2.90%
-0.1

2.90%

Race: More
than one

Count

3

4

7

42.90%
4.70%
0.7
4

57.10%
2.90%
-0.7
7

100.00%
3.40%

Race: Other

% within sample
% within treatment
Adjusted Residual
Count
% within sample

36.40%

63.60%

100.00%

% within treatment

6.30%

5.00%

5.40%

Adjusted Residual
Count

0.4
64

-0.4
140

204

% within sample

31.40%

68.60%

100.00%

% within treatment

100.00%

100.00%

100.00%

Race: White

Race: Black

Race: Asian

Total

60

25

6

11

Table 8E.
Chi Square Tests: Ethnicity and Treatment

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear Association
N of Valid Cases

Asymptotic Significance
df (2-sided)
1
0.151
1
0.174
1
0.152

Value
2.061
1.852
2.052
228

Table 8F.
Treatment Counts Across Ethnicity

Non-Hispanic

Hispanic

Total

No History
of Treatment

History of
Treatment

Total

Count

35

169

204

% within sample
%within treatment

17.20%
83.30%

82.80%
90.90%

100.00%
89.50%

Adjusted Residual

-1.4

1.4

Count

7

17

24

% within sample

29.20%

70.80%

100.00%

%within treatment

16.70%

9.10%

10.50%

Adjusted Residual

1.4

-1.4

Count

42

186

228

% within sample

18.40%

81.60%

100.00%

%within treatment

100.00%

100.00%

100.00%

Table 9A.
Sex and Quality of Life (Year 1)
(n = 218)
Source
Corrected Model
Intercept
Any Treatment
Sex
Any Treatment Sex Interaction
Error
Total
Corrected Total

df

F
3
1
1
1
1
214
218
217

4.409
2598.009
13.216
0.152
0.078

61

Partial Eta
Sig.
Squared
0.005
0.058
<.001
0.924
<.001
0.058
0.697
0.001
0.78
.000

Table 9B.
Sex and Quality of Life (Year 4)
(n = 78)
Source
Corrected Model
Intercept
Any treatment
Sex

3
1
1
1

0.676
927.7
0.668
0.088

0.569
<.001
0.416
0.767

Partial Eta
Squared
0.027
0.926
0.009
0.001

1
74
78

0.983

0.325

0.013

df

Any Treatment Sex Interaction
Error
Total

F

Sig.

Table 9C.
Chi Square Tests: Sex and Treatment

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear Association
N of Valid Cases

Value
1.798
1.799
1.79
228

df
1
1
1

Asymptotic Significance (2-sided)
0.18
0.18
0.181

Table 9D.
Treatment Counts Across Sex

Female

Male

Total

Count
% within sample
% within treatment
Adjusted Residual
Count
% within sample
% within treatment
Adjusted Residual
Count

No History of
Treatment
18
15.10%
42.90%
-1.3
24
22.00%
57.10%
1.3
42

History of
Treatment
101
84.90%
54.30%
1.3
85
78.00%
45.70%
-1.3
186

% within sample
% within treatment

18.40%
100.00%

81.60%
100.00%
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Total
119
100.00%
52.20%
109
100.00%
47.80%
228
100.00%
100.00%

Figures
Figure 1.
Hierarchical model predicting quality of life among college students with and without ADHD

63

Figure 2.
Hierarchical model predicting quality of life among college students with ADHD
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Figure 3A.

Figure 3B.
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Figure 3C.

Figure 3D.
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Figure 4A.

Figure 4B.
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Appendices
Appendix A: Post-hoc analyses
Post-hoc 1
A post-hoc factorial ANOVA (n = 148) was performed to examine whether a difference exists in QoL among college students with ADHD according to when they
stopped receiving medication and psychosocial treatment prior to college (i.e., elementary school, middle school, or high school). No significant difference was found in QoL,
as measured by the “Living with ADHD” subscale of the ADHD Impact module, according to when treatment was ceased (F(14, 59) = 1.460, p = .156).
Table 10.
Cessation of Treatment
(n = 148)
Source
Corrected Model
Intercept
Cessation of Medication
Cessation of Therapy
Interaction of Cessation of Medication
and Cessation of Therapy
Error
Total
Corrected Total

df F
Sig.
14
1.46 0.156
1 1414.583 <.001
3
2.188 0.099
3
1.753 0.166
8
59
74
73

1.077 0.392

Post-hoc 2A
To evaluate whether there are differences in QoL between participants who began
medication before or during the first year of college, a one-way ANOVA (n = 204) was
performed with the grouping variable of first medication use (i.e., never, before college,
during college). The overall model was significant (F(2, 201) = 13.511, p < .001, η2p =
.139), with those who began taking medication before college reporting significantly
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higher quality of life in their first year of college compared to those who had never taken
medication (p < .001). Participants who began taking medication during college did not
report significantly greater quality of life than those who had never taken medication.
Thus, beginning medication before the first year of college appears to predict higher QoL
in the first year of college than prior medication use (See Table 11A). It should be noted,
however, that only n = 7 participants reported beginning medication in the first year of
college. Therefore, there may not have been a large enough sample to adequately reflect
the role of beginning medication in the first year of college.
Table 11A.
Quality of Life and First Medication
(n = 204)
Source
df
F
Corrected Model
2
13.511
Intercept
1
1256.75
First Medication
2
13.511
Error
201
Total
204
Corrected Total
203

Sig.
Partial Eta Squared
<.001
0.119
<.001
0.862
<.001
0.119

Post-hoc 2B
An ANOVA (n = 204) was performed to examine whether a difference in quality
of life exists according to when participants began psychosocial treatment (i.e., never, before college, or during college). The overall model was significant (F(2, 201) = 3.270, p
= .040, η2p = .617; See Table 11B). Specifically, Bonferroni follow up tests revealed that
beginning therapy before college significantly improved QoL beyond a history of no therapy (p = .039), but that beginning therapy in the first year of college did not significantly
improve QoL when compared to a history of no therapy or therapy beginning before the
first year of college.
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Table 11B.
Quality of Life and First Therapy
(n = 204)
Source
df
F
Sig.
Partial Eta Squared
Corrected Model
2
3.27 0.040
0.032
Intercept
1
1514.499 <.001
0.883
First Therapy
2
3.27 0.040
0.032
Error
201
Total
204
Corrected Total
203
Post-hoc 2C
A multiple regression was performed to evaluate the contribution of beginning
medication or therapy in elementary school, middle school, and high school (n = 218).
The overall model was significant (F(4, 213) = 6.328, p < .001) and accounted for 8.9%
of the variance in quality of life. The results of this multiple regression suggested that
first endorsement of medication use in elementary school (ß = .272, p < .001) and first
endorsement of medication use in high school (ß = .220, p = .002) are significant predictors of increased quality of life in the first year of college. No participants in the ADHD
group endorsed the commencement of therapy in middle or high school, and these variables were dropped from the model. Commencement of therapy in elementary school was
not a significant predictor of quality of life in the first year of college (ß = .108, p = .111).
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Table 11C.
Medication and Therapy Before College
(n = 218)
B
Std. Error
Beta
Medication: Elementary
School
7.939
2.071 0.272
Medication: Middle School
6.076
3.164 0.133
Medication: High School
6.971
2.257 0.220
Therapy: Elementary
School
2.766
1.728 0.108

t

Sig.

3.834 <.001
1.92 0.056
3.089 0.002
1.601 0.111

Post-hoc 3
To assess the role of executive functioning, the global, composite score of the
BRIEF used in previous analyses was replaced by the metacognition and behavior regulation indices in the regressions used to test Hypothesis 2 (n = 203). The overall model was
significant (F(10) = 4.412, p < .001) and accounted for 14.5% of the variance in quality
of life, as measured by the “Living with ADHD” subscale of the AIM. The significant
predictors in this model were behavioral regulation index score (ß = -.191, p = .027), metacognition index score (ß = -.207, p = .013), and a history of any treatment (ß = .239, p <
.001). When a history of both forms of treatment was added to the model containing a
history of any treatment, the model remained significant (F(11) = 5.032, p < .001) and accounted for 18.0% of the variance in quality of life. The significant predictors in this
model were behavioral regulation index score (ß = -.214, p = .012), metacognition index
score (ß = -.188, p = .022), a history of any treatment (ß = .147, p = .043), and a history
of both forms of treatment (ß = .221, p = .003). Next, the variable representing any form
of treatment was removed. The overall model was significant (F(10) = 5.040, p < .001)
and accounted for 16.7% of the variance in quality of life. The significant predictors in
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this model were behavioral regulation index score (ß = -.215, p = .012), metacognition index score (ß = -.190, p = .022), and a history of both forms of treatment (ß = .282, p <
.001). Finally, the treatment variable was parsed into medication and therapy. The overall
model was significant (F(11) = 5.251, p < .001) and accounted for 18.8% of the variance
in quality of life. The significant predictors in this model were behavioral regulation index score (ß = -.206, p = .015), metacognition index score (ß = -.188, p = .022), and a history of medication (ß = .275, p < .001). These results indicate that the two index scores of
the BRIEF, the metacognition index and behavioral regulation index, are predictive of
quality of life along with global executive functioning.
Table 12.
Executive Functioning Subscales
(n = 203)
Sex
Ethnicity
Race: White
Race: Black
Race: Asian
Race: More than one
CAARS DSM Total Score
BRIEF: BRI
BRIEF: MI
Any treatment

B
Std. Error
Beta
t
Sig.
-0.114
1.747 -0.004 -0.065 0.948
3.614
3.469
0.086
1.042 0.299
6.19
4.867
0.205
1.272 0.205
2.272
5.386
0.058
0.422 0.674
2.799
6.915
0.037
0.405 0.686
4.019
6.523
0.057
0.616 0.539
0.028
0.108
0.02
0.261 0.794
-0.228
0.103 -0.191 -2.222 0.027
-0.18
0.072 -0.207
-2.5 0.013
7.573
2.117
0.239
3.577 <.001

Post-hoc 4
To further understand the relationship between treatment and race, treatment was
parsed into medication and therapy and a second chi square test (n = 228) was performed
to identify whether there existed significant differences across race in endorsement of
medication and therapy separately. Regarding medication, the chi square test was significant (chi square (4, N = 228) = 12.88, p = .012). White students with ADHD endorsed the
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greatest rates of medication use (83.40%), followed by Black students (6.6%), students of
more than one race (3.3%), students of other races (4.0%), and Asian students (2.6%).
Despite being the second largest group to endorse medication use, Black participants
were the only category in which fewer students endorsed medication use (40%) than a
lack of medication use (60%) and were the most likely to report no use of medication (z =
2.9). Regarding therapy, the chi square test was not significant across race (chi square (4,
n = 228) = 1.361, p = .851).
Table 13A.
Chi Square: Race and Medication
(n = 228)

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear Association
N of Valid Cases

Value
df
12.887 4
12.296 4
5.391 1
228

73

Asymptotic Significance
(2-sided)
0.012
1.50
0.02

Table 13B.
Race and Medication
(n = 228)
Race:
Asian

Race:
More
than one

2

5

63.60% 19.50% 2.60%

6.50%

Race:
White
No History of
Medication

Count
% within
medication

History of
Medication

49

Race:
Black

15

Race:
Other

6

-3.3

2.9

0

1.1

1.2

Count

126

10

4

5

6

6.60% 2.60%

3.30%

83.40%

Adjusted
Residual
Count

3.3
175

-2.9
25

0
6

-1.1
10

77

7.80% 100.00%

Adjusted
Residual

%within
medication

Total

151

4.00% 100.00%
-1.2
12

228

Table 13C.
Chi Square: Race and Therapy
(n = 228)

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear Association
N of Valid Cases

Value
df
1.361b
4
1.487 4
0.099 1
228

74

Asymptotic Significance
(2-sided)
0.851
0.829
0.754

Table 13D.
Race and Therapy
(n = 228)
Race:
White
No History of
Therapy

History of
Therapy

Count

Race:
Black

Race:
Asian

Race:
More
than one

Race:
Other

Total

63

10

1

4

5

% within
therapy

75.90%

12.00%

1.20%

4.80%

Adjusted
Residual

-0.2

0.4

-1

0.2

0.4

Count

112

15

5

6

7

% within
therapy

77.20%

10.30%

3.40%

4.10%

Adjusted
Residual

0.2

-0.4

1

-0.2

83

6.00% 100.00%

145

4.80% 100.00%
-0.4

Post-hoc 5
To explore racial differences in the treatment of ADHD further, disparities in diagnosis of ADHD were explored according to race using a chi square test. The test was
significant (chi square (4, n = 456) = 10.443, p = .03), suggesting that White college students were significantly more likely to be diagnosed with ADHD (z = 2.4, 76.80%) and
Asian students were significantly less likely to be diagnosed with ADHD (z = -2.7,
2.60%).
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Table 14A.
Chi Square: Race and Diagnosis of ADHD
(n = 228)
Value
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear Association
N of Valid Cases

Asymptotic
Significance
(2-sided)

df

10.443
10.797
3.037
456

4
4
1

0.034
0.029
0.081

Table 14B.
Race and Diagnosis of ADHD
(n = 228)
Race:
White
ADHD
Diagnosis

No ADHD
Diagnosis

Count
% within
sample
Adjusted
Residual
Count
% within
sample
Adjusted
Residual
Count
% within
group.1:
Group

175

Race:
Black
25

Race:
Asian

Race:
More
than
one

Race:
Other

6

10

76.80% 11.00% 2.60%

4.40%

12

-0.9

-2.7

0.5

-1.1

152

31

19

8

18

66.70% 13.60% 8.30%

3.50%

0.9
56

2.7
25

-0.5
18

71.70% 12.30% 5.50%

3.90%

76

228

5.30% 100.00%

2.4

-2.4
327

Total

228

7.90% 100.00%
1.1
30

456

6.60% 100.00%

Appendix B
Measures
Demographic, social, and family history questionnaire.
A questionnaire designed by the research team was administered at the first point
of assessment in Year 1 to inquire about demographic information. Data including race,
ethnicity, sex, and age were collected, as well as information concerning an individual’s
family structure and medical history.
Services for College Students Interview (SCSI).
A 13-question self-report measure designed specifically for use in the TRAC project was administered in Year 1 of assessment to measure student’s engagement and satisfaction with psychosocial and psychological services and treatment modalities. The items
of this measure inquire about students’ utilization of health services, including psychosocial and psychopharmacological treatments (Pinho et al., 2019). For the purposes of the
proposed study, participation in psychosocial and psychopharmacological treatments was
defined as any participation in treatment reported from elementary school to current use.
Two versions of the SCSI were used, one which assessed services prior to college and one
which assessed services during college.
ADHD Impact Module (AIM): Global and Subscales.
The purpose of this measure is to assess the level of interference of symptoms of
ADHD on QoL. The measure was administered at each time point of assessment. The AIM
measures QoL in six domains (i.e., Living with ADHD; General Well-Being; Work, Home,
and School Performance and Daily Functioning; Relationships and Communication; Impact of Symptoms) using a Likert scale of five points. The AIM is scored on a standard
scale from 0 to 100, with a higher score reflecting greater QoL. The measure has good
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internal consistency (! ≈ .68-.91) and has been shown to be highly correlated with other
measures of QoL and is sensitive to change (Landgraf, 2007).
Conners’ Adult ADHD Rating Scales (CAARS).
A self-report scale measuring inattention and hyperactivity in individuals over the
age of 18 was administered to assess ADHD symptom severity at each of the four assessment points. Psychometric calculations reveal that the internal consistency of the CAARS
is very good to excellent (! ≈.74-.94; Adler et al., 2008). Unfortunately, little research has
been performed concerning the validity of the CAARS in minoritized populations. Analyses using data from this measure must be performed carefully to assess for potential biases. Higher scores on the CAARS indicate greater presence of ADHD symptomology.
Behavior Rating Inventory of Executive Function (BRIEF).
The purpose of this assessment is to measure executive functioning ability (Gioia
et al., 2000). The BRIEF has a two-factor composition: Behavioral Regulation, composed
of Inhibit, Self-Monitor, and Emotional Regulation subfactors; and Metacognition (Roth
et al., 2013). Convergent validity between the BRIEF and other measures of executive
functioning (e.g., Behavior Assessment System for Children) is acceptable for each subscale (.24-.83) (McCandless & O’Laughlin, 2007). The BRIEF has been found to have
adequate psychometric properties in individuals with ADHD and neurotypical individuals
(Roth et al., 2013). Higher scores on the BRIEF reflect higher executive dysfunction. The
BRIEF was administered at each time point of assessment over the four years of data collection.
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Appendix C
Demographic, Social, and Family History Questionnaire
Demographic Information
1. Age (in years):
________
2. Gender (0 = female, 1 = male):
________
3. Ethnicity (Non-Hispanic = 0, Hispanic = 1):
________
4. Race:
________
1 = Caucasian
2 = African American
ported

3 = Asian
4 = Native American

5 = More than 1 race
6 = Other/Not Re-

5. Marital status (1 = Single, 2 = Married, 3 = Separated, 4 = Divorced)
Social History
1. Prior Fraternity/Sorority
________
2. Current Fraternity/Sorority
________
3. Prior University Sports Team
________
4. Current University Sports Team
________
5. Prior club sports/intramural sports
________
6. Current club sports/intramural sports
________
7. Prior university club/organizations
________
8. Current university club/organizations
________
9. Prior committed relationship
________
10. How many committed relationships
________
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(Yes = 1, No = 0)
(Yes = 1, No = 0)
(Yes = 1, No = 0)
(Yes = 1, No = 0)
(Yes = 1, No = 0)
(Yes = 1, No = 0)
(Yes = 1, No = 0)
(Yes = 1, No = 0)
(Yes = 1, No = 0)
( Enter number )

11. Current committed relationship
________
Family Background (Current Family)

(Yes = 1, No = 0)

1. Number of siblings (#):
________
2. Parents’ marital status (1-5):
________
3. Mother’s education (1 -7):
________
4. Father’s education (1-7):
________
5. Mother’s occupation (2-digit NPB score):
________
6. Father’s occupation (2-digit NPB score):
________

Family History (Current Family)
1. ADHD:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

2. Oppositional-Defiant Disorder:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

3. Conduct Disorder:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

4. Learning Disability:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

5. Autism:
________

a. Self
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b. Other family

b. Other family

b. Other family

b. Other family

(0 = none, 1 = suspected, 2 = diagnosed)
________

b. Other family

6. Asperger’s:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

7. Psychosis/Schizophrenia :
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

8. Depressive Disorder:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

9. Bipolar Disorder:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

10. Anxiety Disorder:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

11. Obsessive-Compulsive Disorder:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

12. PTSD:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

13. Anorexia/Bulimia:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

14. Tics/Tourette’s:
________

a. Self
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b. Other family

b. Other family

b. Other family

b. Other family

b. Other family

b. Other family

b. Other family

b. Other family

(0 = none, 1 = suspected, 2 = diagnosed)
________

b. Other family

15. Alcohol Abuse:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

16. Substance Abuse:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

17. Seizures/Epilepsy:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

18. Head Injury:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

19. Thyroid Condition:
________
(0 = none, 1 = suspected, 2 = diagnosed)
________

a. Self

20. Sleep Problems
________
(0 = none, 1 = suspected, 2 = diagnosed)
_________

b. Other family

b. Other family

b. Other family

b. Other family

b. Other family
a. Self
b. Other family
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Appendix D
ID: __________
Date: __________
Services for College Students Interview (SCSI)
Pre-College

Directions: I am now going to ask you questions about help or
assistance you may have received prior to attending college.

1. At any time from kindergarten through high school, did you ever YES NO
receive extra help in school for any attentional, learning, emotional,
and/or behavioral difficulties?
If NO, skip to Question #4; if YES, ask:
2. Was this extra help provided through an IEP or Individualized Education
Program? YES NO
If NO, skip to Question #3; if YES, ask:
a. What is the main reason you received IEP services? _____ (1 = ADHD, 2 = LD, 3
= emotional/behavioral difficulties, 4 = other)
b. When did you begin receiving IEP services? _____ (1 = elementary school, 2 =
middle school, 3 = high school)
c. When did you last receive IEP services? _____ (1 = elementary school, 2 = middle
school, 3 = high school)
d. In your opinion, how helpful were these IEP services? _____ (1 = not very helpful,
2 = moderately helpful, 3 = very helpful)
3. Did you receive 504 accommodations? Informal accommodations? YES NO
If NO, skip to Question #4; if YES to either, ask:
a. What is the main reason you received [name] accommodations? _____ (1 = ADHD,
2 = LD, 3 = emotional/behavioral difficulties, 4 = other)
b. When did you begin receiving [name] accommodations? _____ (1 = elementary
school, 2 = middle school, 3 = high school)
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c. When did you last receive [name] accommodations? _____ (1 = elementary school,
2 = middle school, 3 = high school)
d. In your opinion, how helpful were these [name] accommodations? _____ (1 = not
very helpful, 2 = moderately helpful, 3 = very helpful)
4. At any time from kindergarten through high school, did you ever take medication for ADHD-related difficulties? YES NO
If NO, skip to Question #6 if YES, ask:
a. What was the name of the medication prescribed for you the very first time? _____
(1 = MPH, 2 = Amphetamine, 3 = non-stimulant ADHD, 4 = other)
b. Who prescribed [name of medication]? _____ (1 = pediatrician, 2 = psychiatrist, 3
= other)
c. When did you first begin taking [name of medication]? _____ (1 = elementary
school, 2 = middle school, 3 = high school)
d. How many times per day did you take [name of medication]? _____ (1 = once daily,
2 = twice daily, 3 = 3+ times daily)
e. How many days per week did you take [name of medication]? _____ (1 = every day,
2 = weekdays only, 3 = as needed)
f. When did you stop taking [name of medication]? _____ (1 = elementary school, 2 =
middle school, 3 = high school, 4 = still taking)
g. In your opinion, how helpful was taking [name of medication]? _____ (1 = not very
helpful, 2 = moderately helpful, 3 = very helpful)
h. What side effects (if any) did taking [name of medication] cause you? _____ (1 =
appetite loss, 2 = sleep disruption, 3 = irritability, 4 = other)
5. Prior to college did you take any other medications for ADHD-related difficulties? YES NO
If NO, skip to Question #6; if YES, ask:
a. What was the name of the medication prescribed for you most recently? _____ (1 =
MPH, 2 = Amphetamine, 3 = non-stimulant ADHD, 4 = other)
b. Who prescribed [name of medication]? _____ (1 = pediatrician, 2 = psychiatrist, 3
= other)
c. When did you first begin taking [name of medication]? _____ (1 = elementary
school, 2 = middle school, 3 = high school)
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d. How many times per day did you take [name of medication]? _____ (1 = once daily,
2 = twice daily, 3 = 3+ times daily)
e. How many days per week did you take [name of medication]? _____ (1 = every day,
2 = weekdays only, 3 = as needed)
f. When did you stop taking [name of medication]? _____ (1 = elementary school, 2 =
middle school, 3 = high school, 4 = still taking)
g. In your opinion, how helpful was taking [name of medication]? _____ (1 = not very
helpful, 2 = moderately helpful, 3 = very helpful)
h. What side effects (if any) did taking [name of medication] cause you? _____ (1 =
appetite loss, 2 = sleep disruption, 3 = irritability, 4 = other)
6. Prior to college , did you ever take medication for other types of behavioral or
emotional difficulties? YES NO
If NO, skip to Question #7; if YES, ask:
a. What medication(s) did you take? _____ (1 = mood, 2 = anxiety, 3 = other)
b. What was the main reason for taking [name of medication]? _____ (1 = depression,
2 = anxiety, 3 = anger, 4 = other)
c. Who prescribed [name of medication]? _____ (1 = pediatrician, 2 = psychiatrist, 3
= other)
d. When did you first begin taking [name of medication]? _____ (1 = elementary
school, 2 = middle school, 3 = high school)
e. How many times per day did you take [name of medication]? _____ (1 = once daily,
2 = twice daily, 3 = 3+ times daily)
f. How many days per week did you take [name of medication]? _____ (1 = every day,
2 = weekdays only, 3 = as needed)
g. When did you stop taking [name of medication]? _____ (1 = elementary school, 2
= middle school, 3 = high school, 4 = still taking)
h. In your opinion, how helpful was taking [name of medication]? _____ (1 = not very
helpful, 2 = moderately helpful, 3 = very helpful)

7. At any time from kindergarten through high school, did you ever receive individual, group, or family counseling/therapy? YES NO
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If NO, end interview; if YES, ask:
a. What was the first type of counseling/therapy that you ever received? _____ (1 =
individual, 2 = group, 3 = family)
b. What is the main reason you received [name of counseling/therapy]? _____ (1 =
ADHD, 2 = depression, 3 = anxiety, 4 = anger, 5 = other)
c. When did you first begin receiving [name of counseling/therapy]? _____ (1 = elementary school, 2 = middle school, 3 = high school)
d. How often did you participate in or attend [name of counseling/therapy]? _____ (1=
weekly, 2 = alternate weeks, 3 = once a month, 4 = other)
e. When did you stop receiving [name of counseling/therapy]? _____ (1 = elementary
school, 2 = middle school, 3 = high school, 4 = still receiving)
f. In your opinion, how helpful was [name of counseling/therapy]? _____ (1 = not very
helpful, 2 = moderately helpful, 3 = very helpful)
8. In addition to [name of counseling/therapy], did you receive any other counseling or therapy? YES NO
If NO, end interview; if YES, ask:
a. What type of counseling/therapy did you receive most recently? _____ (1 = individual, 2 = group, 3 = family)
b. What is the main reason you received [name of counseling/therapy]? _____ (1 =
ADHD, 2 = depression, 3 = anxiety, 4 = anger, 5 = other)
c. When did you first begin receiving [name of counseling/therapy]? _____ (1 = elementary school, 2 = middle school, 3 = high school)
d. How often did you participate in or attend [name of counseling/therapy]? _____ (1=
weekly, 2 = alternate weeks, 3 = once a month, 4 = other)
e. When did you stop receiving [name of counseling/therapy]? _____ (1 = elementary
school, 2 = middle school, 3 = high school, 4 = still receiving)
f. In your opinion, how helpful was [name of counseling/therapy]? _____ (1 = not very
helpful, 2 = moderately helpful, 3 = very helpful)
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Appendix E
ID:
Date:

Services for College Students Interview (SCSI)College
Version – Year 1
Directions: I am now going to ask you questions about any help or assistance you
may have received during the current school year; that is, from the beginning of
thefall semester to the present.

1. Not including required meetings, did you meet with a professor or your

YES
NO
academic advisor to discuss your academic performance/progress?
If NO, skip to Question #2; if YES, ask:
a. With whom did you meet to dis-

cuss most of your concerns? (1 =
advisor, 2 = course professor, 3 =
other)
b. What was the reason you met with [name of faculty]?

(1 = not doing well, 2 = bad test/paper grade, 3 = help with assignment, 4 = other)
c. How many times did you

meet with [name of faculty]?
(1 = 1-2 times, 2 = 3-4 times,
3 = 5+ times)
d. In your opinion, how well did [name of faculty] listen and try to

understand your concerns? (1 = not well, 2 = moderately well, 3 =
very well)
e. What assistance or accommodations, if any, did [name of faculty] offer?
(1 = none, 2 = studying advice, 3 = extra credit opportunity, 4 = extended deadline, 5 =
other)
f.

In your opinion, how helpful was this assistance
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from [name of faculty]? (1 = not helpful, 2 =
moderately helpful, 3 = very helpful)

2. At any time since the fall semester began, did you receive campus

YES
NO
tutoring services?

If NO, skip to #3; if YES, ask:
a. How many times did you receive tutoring?

(1 = 1-2 times, 2 = 3-4 times, 3 = 5 -9 times, 4 = 10 or more times)
b. Are you still receiving tutoring?
(1 = still receiving, 2 = stopped receiving)
c. In your opinion, how helpful was tutoring?
(1 = not very helpful, 2 = moderately helpful, 3 = very helpful)Since the fall semester began, did you receive academic skills YES NO
assistance (e.g., planners, organization, time management, etc.)?

If NO, skip to #4; if YES, ask:
d. How many times did you receive study skills assistance?
(1 = 1-2 times, 2 = 3-4 times, 3 = 5 – 9 times, 4 = 10 or more times)
e. Are you still receiv-

ing study skills assistance? (1 = still receiving, 2 = stopped
receiving)
In your opinion, how helpful was study skills assistance?
(1 = not very helpful, 2 = moderately helpful, 3 = very helpful)
f.

3. From the beginning of the fall semester until now, did you receive

YES
NO
writing/speaking assistance?
If NO, skip to #5; if YES, ask:
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a. How many times did you receive writing/speaking assistance?
(1 = 1-2 times, 2 = 3-4 times, 3 = 5 - 9 times, 4 = 10 or more times)
b. Are you still receiving

writing/speaking assistance? (1 = still receiving,
2 = stopped receiving)
c. In your opinion, how helpful was

writing/speaking assistance? (1 = not
very helpful, 2 = moderately helpful, 3
= very helpful)

4. During this same time period, did you receive career counseling?

YES
NO
If NO, skip to #6; if YES, ask:
a. How many times did you receive career counseling?

(1 = 1-2 times, 2 = 3-4 times, 3 = 5 – 9 times, 4 = 10 or more times)
b. Are you still re-

ceiving career
counseling? (1 =
still receiving, 2
= stopped receiving)
c. In your opinion, how helpful was career counseling?

(1 = not very helpful, 2 = moderately helpful, 3 = very helpful)
5. At any time since the fall semester began, did you receive formal
YES
NO
disability service accommodations?
If NO, skip to Question #7; if YES, ask:
Which of the following types of accommodations did you receive?
a. Extra time (1 = Yes, 0 = No)
b. Private testing room (1 = Yes, 0 = No)
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c. Note-taker (1 = Yes, 0 = No)
d. Technology support (1 = Yes, 0 = No)
e. Other (1 = Yes, 0 = No)
f.

What is the main reason you received
these accommodations? (1 = ADHD, 2
= LD, 3 = other emotional/behavioral
difficulties)

g. How long did you receive these accommodations?
(1 = less than 1 month, 2 = 1-2 months, 3 = 3+ months)
h. How regularly did you use these accommodations?

(1 = not at all, 2 = sometimes, 3 = often, 4= very often)
i.

Are you still using these accommodations? (1 =
still using, 2 =
stopped using)

In your opinion, how helpful are these accommodations?
(1 = not very helpful, 2 = moderately helpful, 3 = very helpful)
j.

6. At any time since the start of the fall semester, did you take medication for

YES
NO
ADHD-related difficulties?
If NO, skip to Question #10; if YES, ask:
a. What is the name of the medication?

(1 = MPH, 2 = Amphetamine, 3 = non-stimulant ADHD, 4 = other)
b. Who prescribed or gave you [name of medication]?
(1 = primary care physician, 2 = psychiatrist, 3 = other physician, 4 = another student)
c. How long did you take [name of medication]?
(1 = less than 1 month, 2 = 1-2 months, 3 = 3+ months)
d. How many times per day did you
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take [name of medication]? (1 =
once, 2 = twice, 3 = 3+)
e. How many days per week were you supposed to

take [name of medication]? (1 = daily, 2 = weekdays only, 3 = as needed)
How closely did you follow this [name
of medication] regimen? (1 = not well,
2 = moderately well, 3 = very well)
g. Are you still taking [name of
medication]? (1 =
still taking, 2 =
stopped taking)
f.

h. In your opinion, how helpful was tak-

ing [name of medication]? (1 = not
very helpful, 2 = moderately helpful, 3
= very helpful)
Did taking [name of medication] cause any of the following side effects?
i.

Loss of appetite (1 = Yes, 0 = No)

j.

Sleep disruption (1 = Yes, 0 = No)

k. Irritability (1 = Yes, 0 = No)
l.

Other (1 = Yes, 0 = No)

7. Did you take any other medication for ADHD-related difficulties?

YES
NO
If NO, skip to Question #10; if YES, ask:
a. What is the name of that medication?

(1 = MPH, 2 = Amphetamine, 3 = non-stimulant ADHD, 4 = other)
b. Who prescribed or gave you [name of medication]?
(1 = primary care physician, 2 = psychiatrist, 3 = other physician, 4 = another student)
c. How long did you take [name of medication]?
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(1 = less than 1 month, 2 = 1-2 months, 3 = 3+ months)
d. How many times per day did you

take [name of medication]? (1 =
once, 2 = twice, 3 = 3+)
e. How many days per week were you supposed to

take [name of medication]? (1 = daily, 2 = weekdays only, 3 = as needed)
f.

How closely did you follow this [name
of medication] regimen? (1 = not well,
2 = moderately well, 3 = very well)

g. Are you still tak-

ing [name of
medication]? (1 =
still taking, 2 =
stopped taking)
h. In your opinion, how helpful was tak-

ing [name of medication]? (1 = not
very helpful, 2 = moderately helpful, 3
= very helpful)
Did taking [name of medication] cause any of the following side effects?
i.

Loss of appetite (1 = Yes, 0 = No)

j.

Sleep disruption (1 = Yes, 0 = No)

k. Irritability (1 = Yes, 0 = No)

Other (1 = Yes, 0 = No)
8. In addition to [name of ADHD medications], did you take any other
YES
NO
medication for ADHD-related difficulties?
l.

If NO, skip to Question #10; if YES, ask:
a. What is the name of that medication?
(1 = MPH, 2 = Amphetamine, 3 = non-stimulant ADHD, 4 = other)
b. Who prescribed or gave you [name of medication]?

(1 = primary care physician, 2 = psychiatrist, 3 = other physician, 4 = another student)
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c. How long did you take [name of medication]?
(1 = less than 1 month, 2 = 1-2 months, 3 = 3+ months)
d. How many times per day did you

take [name of medication]? (1 =
once, 2 = twice, 3 = 3+)
e. How many days per week were you supposed to

take [name of medication]? (1 = daily, 2 = weekdays only, 3 = as needed)
f.

How closely did you follow this [name
of medication] regimen? (1 = not well,
2 = moderately well, 3 = very well)

g. Are you still tak-

ing [name of
medication]? (1 =
still taking, 2 =
stopped taking)
h. In your opinion, how helpful was tak-

ing [name of medication]? (1 = not
very helpful, 2 = moderately helpful, 3
= very helpful)
Did taking [name of medication] cause any of the following side effects?
i.

Loss of appetite (1 = Yes, 0 = No)

j.

Sleep disruption (1 = Yes, 0 = No)

k. Irritability (1 = Yes, 0 = No)
l.

Other (1 = Yes, 0 = No)

9. Since the fall semester began, did you take medication for any other

YES
NO
behavioral or emotional difficulties?

If NO, skip to Question #12; if YES, ask:
a. What medication(s) did you take? (1 = mood, 2 = anxiety, 3 = other)
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b. What was the main reason for taking [name of medication]? (1 = depres-

sion, 2 = anxiety, 3 = anger, 4 = other)
c. Who prescribed or gave you [name of medication]?

(1 = primary care physician, 2 = psychiatrist, 3 = another student)
d. How long did you take [name of medication]?
(1 = less than 1 month, 2 = 1-2 months, 3 = 3+ months
e. Are you still taking [name of medication]? (1 = still taking, 2 = stopped
taking)
f.

In your opinion, how helpful was taking [name of medication]? (1 = not
very helpful, 2 = moderately helpful, 3 = very helpful)

10. In addition to [name of medication], did you take any other

YES
NO
medication for these other types of behavioral or emotional difficulties?
If NO, skip to Question #12; if YES, ask:
a. What other medication(s) did you take? (1 = mood, 2 = anxiety, 3 =

other)
b. What was the main reason for taking [name of medication]? (1 = depres-

sion, 2 = anxiety, 3 = anger, 4 = other)
c. Who prescribed or gave you [name of medication]?

(1 = primary care physician, 2 = psychiatrist, 3 = another student)
d. How long did you take [name of medication]?

(1 = less than 1 month, 2 = 1-2 months, 3 = 3+ months)
e. Are you still taking [name of medication]? (1 = still taking, 2 = stopped

taking)
f.

In your opinion, how helpful was taking [name of medication]? (1 = not
very helpful, 2 = moderately helpful, 3 = very helpful)

11. At any time since classes started last fall, did you participate in or

YES
NO
receive individual or group counseling/ therapy?
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If NO, end Interview; if YES, ask:
a. What kind of counseling/therapy did you receive? (1 = individual, 2 =

group, 3 = family)
b. What is the main reason you received [name of counseling/therapy]? (1 =

ADHD, 2 = depression 3 = anxiety, 4 = other)
c. Who provided the [name of counseling/therapy]?

(1 = campus professional, 2 = off-campus professional)
d. How often did you participate in or attend [name of counseling/ther-

apy]? (1 = weekly, 2 = alternate weeks, 3 = once a month, 4 = other)
e. Are you still receiving [name of counseling/therapy]? (1 = still receiving,

2 = stopped receiving)
f.

How closely did you follow the therapy/counseling advice and guidance
you received? (1 = not well, 2 = moderately well, 3 = very well)

g. In your opinion, how helpful was [name of counseling/therapy]? (1 = not

very helpful, 2 = moderately helpful, 3 = very helpful)
12. In addition to [name of counseling/therapy], did you receive any
YES
NO
other counseling or therapy?
If NO, end Interview; if YES, ask:
a. What type of counseling/therapy did you receive? (1 = individual, 2 =

group, 3 = family)
b. What is the main reason you received [name of counseling/therapy]? (1 =

ADHD, 2 = depression 3 = anxiety, 4 = other)
c. Who provided the [name of counseling/therapy]?
(1 = campus professional, 2 = off-campus professional)
d. How often did you participate in or attend [name of counseling/ther-

apy]? (1 = weekly, 2 = alternate weeks, 3 = once a month, 4 = other)
e. Are you still receiving [name of counseling/therapy]? (1 = still receiving,

2 = stopped receiving)
f.

How closely did you follow the therapy/counseling advice and guidance
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you received? (1 = not well, 2 = moderately well, 3 = very well)
g. In your opinion, how helpful was [name of counseling/therapy]? (1 = not

very helpful, 2 = moderately helpful, 3 = very helpful)
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Appendix F
ADHD Impact Module – Adult (AIM-A)
INSTRUCTIONS: The following questions were developed to better understand how issues related to ADHD impact the quality of your everyday life. Your responses will be
treated confidentially. There are no right or wrong responses. If you are unsure how to
respond to a question, give the best response you can. It is very important that you fill in
each question. Please use blue or black ink.
1. On a scale of 1-10, how would you rate the overall quality of your life right now?
(Worst) 1 2 3 4 5 6 7 8 9 10 (Best)
2. Has ADHD and its symptoms limited your ability to achieve what you want in life?
Yes, a lot
Yes, some
Yes, a little No, not at all
3. Do you feel you are on the right track with your life?
Yes, definitely
Yes, somewhat
No, not at all
4. How much do you agree with this statement: “Over the past few weeks, I’ve had
more good days than bad days.”
Strongly agree Agree
Neither agree nor disagree Disagree
Strongly disagree
LIVING WITH ADHD
5. Thinking about your ADHD symptoms, how much do you agree or disagree with
the following?
a. I’ve devised ways to compensate for my ADHD symptoms
Strongly agree Agree
Neither agree nor disagree Disagree
Strongly disagree
b. I’m relieved to finally have an explanation for my difficulties and to have something I can do to correct them
Strongly agree Agree
Neither agree nor disagree Disagree
Strongly disagree
c. I feel as if I am just getting by in life
Strongly agree Agree
Neither agree nor disagree
gree

Disagree

Strongly disa-

d. I regret “things that could have been” or “what ifs”
Strongly agree Agree
Neither agree nor disagree Disagree
gree

Strongly disa-
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e. I don’t want others to know I have ADHD
Strongly agree Agree
Neither agree nor disagree
gree

Disagree

Strongly disa-

f. I have been able to achieve balance in my life by managing my ADHD
Strongly agree Agree
Neither agree nor disagree Disagree
Strongly disagree
g. I’ve turned my life around
Strongly agree Agree
Neither agree nor disagree
gree

Disagree

Strongly disa-

h. I isolate myself from others because of my ADHD
Strongly agree Agree
Neither agree nor disagree Disagree
gree

Strongly disa-

i. Meds help with core symptoms but I still have to work on other issues
Strongly agree Agree
Neither agree nor disagree Disagree
Strongly disagree
j. My ADHD symptoms are no longer controlling my life
Strongly agree Agree
Neither agree nor disagree Disagree
gree

Strongly disa-

GENERAL WELL-BEING
6. Thinking about your ADHD symptoms during the past 7 days, and the feelings they
may cause, how often did you feel:
a. Hopeful about the future
Very often
Fairly often Sometimes
Almost never
Never
b. Frustrated/annoyed
Very often
Fairly often Sometimes
Almost never
Never
c. Tense/stressed
Very often
Fairly often Sometimes
Almost never
Never
d. Ashamed/embarrassed
Very often
Fairly often Sometimes
Almost never
Never
e. Calm/relaxed
Very often
Fairly often Sometimes
Almost never
Never
f. Accepting of yourself
Very often
Fairly often Sometimes
Almost never
Never
g. Mentally exhausted/frazzled
Very often
Fairly often Sometimes
Almost never
Never
h. Confident
Very often
Fairly often Sometimes
Almost never
Never
i. Angry
Very often
Fairly often Sometimes
Almost never
Never
j. As if you had failed
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Very often

Fairly often Sometimes
k. Able to cope
Very often
Fairly often Sometimes

Almost never

Never

Almost never

Never

WORK, HOME, AND SCHOOL – PERFORMANCE AND DAILY FUNCTIONING
7. During the past 7 days, how satisfied have you been with the following?
a. Ability to focus equally well on all tasks and not just those that interest you
Very dissatisfied
Somewhat dissatisfied
Neither satisfied nor dissatisfied
Somewhat satisfied Very satisfied\
b. Ability to take care of everyday responsibilities (pay bills, meet deadlines,
get dinner going, run errands)
Very dissatisfied
Somewhat dissatisfied
Neither satisfied nor dissatisfied
Somewhat satisfied Very satisfied
c. Ability to think things through more carefully and make timely decisions
Very dissatisfied
Somewhat dissatisfied
Neither satisfied nor dissatisfied
Somewhat satisfied Very satisfied
d. Handling everyday hassles
Very dissatisfied
Somewhat dissatisfied
Somewhat satisfied Very satisfied

Neither satisfied nor dissatisfied

e. Ability to adapt to disruptions or unexpected changes in your routine
Very dissatisfied
Somewhat dissatisfied
Neither satisfied nor dissatisfied
Somewhat satisfied Very satisfied
f. Ability to implement ideas/solutions
Very dissatisfied
Somewhat dissatisfied
Neither satisfied nor dissatisfied
Somewhat satisfied Very satisfied
g. Getting organized, prioritizing, starting tasks
Very dissatisfied
Somewhat dissatisfied
Neither satisfied nor dissatisfied
Somewhat satisfied Very satisfied
h. The consistency of your productivity.
Very dissatisfied
Somewhat dissatisfied
Neither satisfied nor dissatisfied
Somewhat satisfied Very satisfied
i. Reacting to other’s annoyances/irritations
Very dissatisfied
Somewhat dissatisfied
Neither satisfied nor dissatisfied
Somewhat satisfied Very satisfied
j. Performing to your full potential
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Very dissatisfied
Somewhat dissatisfied
Somewhat satisfied Very satisfied

Neither satisfied nor dissatisfied

RELATIONSHIPS/COMMUNICATION
8. During the past 7 days, because of issues with ADHD have you had difficulty with:
a. Resolving interpersonal conflicts
No, not at all Yes, a little bit Yes, somewhat Yes, quite a bit Yes, a lot
b. Responding to invitations, emails, calls in a timely way
No, not at all Yes, a little bit Yes, somewhat Yes, quite a bit Yes, a lot
c. Acting logically and rationally with others
No, not at all Yes, a little bit Yes, somewhat Yes, quite a bit Yes, a lot
d. Showing others that you are reliable and committed
No, not at all Yes, a little bit Yes, somewhat Yes, quite a bit Yes, a lot
e. Keeping your train of thought and staying engaged during conversations
No, not at all Yes, a little bit Yes, somewhat Yes, quite a bit Yes, a lot
f. Engaging in physical/sexual intimacy
No, not at all Yes, a little bit Yes, somewhat Yes, quite a bit Yes, a lot
g. Being able to provide emotional support to others
No, not at all Yes, a little bit Yes, somewhat Yes, quite a bit Yes, a lot
h. Reading other’s emotions or non-verbal cues
No, not at all Yes, a little bit Yes, somewhat Yes, quite a bit Yes, a lot
IMPACT OF SYMPTOMS ON DAILY LIFE
9. The following question asks about common ADHD symptoms. There are two parts
to the question. Fill in the box that corresponds to your response for each part of
the question.
How much do the following symptoms:
A. BOTHER OR CONCERN YOU? B. INTERFERE WITH DAILY LIFE?
1 = Not at all 2. A little bit 3. Some 4. Quite a bit 5. A lot
a. Being distracted and jumping from one activity to another
A: 1 2 3 4 5 B: 1 2 3 4 5
b. Being unable to start/finish tasks that don’t interest you
A: 1 2 3 4 5 B: 1 2 3 4 5
c. Feeling lost or in a fog
A: 1 2 3 4 5 B: 1 2 3 4 5
d. Sudden mood changes triggered by life events
A: 1 2 3 4 5 B: 1 2 3 4 5
e. Interrupting/blurting things out
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f.
g.
h.
i.

A: 1 2 3 4 5 B: 1 2 3 4 5
Difficulty turning off your mind to fall asleep and/or trouble being alert in
the morning
A: 1 2 3 4 5 B: 1 2 3 4 5
Being overly sensitive to others comments/criticisms
A: 1 2 3 4 5 B: 1 2 3 4 5
Intense temper outbursts that pass quickly
A: 1 2 3 4 5 B: 1 2 3 4 5
Forgetfulness/losing things
A: 1 2 3 4 5 B: 1 2 3 4 5

ECONOMIC IMPACTS (please respond to these questions as best as you can remember)
10. Number of motor vehicle infringements during the last year __
11. Number of jobs you’ve had to date __
12. Number of visits to the ER/Doctor for injuries/accidents in the past year (not motor
vehicle accidents) __
13. Number of visits to the doctor in the past year regarding ADHD (can be medical,
psychiatrist, other) __
14. Number of days missed from work/school in the past year due to ADHD __
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Appendix G
CAARS- Self-Report: Long Version (CAARS- S:L)
Instructions: listed below are items concerning behaviors or problems sometimes experienced by adults. Read each item carefully and decide how much or how frequently each
item describes you recently. Indicate your response for each item that corresponds to your
choice. Use the following scale: 0 – Not at all, never; 1 – Just a little, once in a while; 2 –
pretty much, often; and 3 – Very much, very frequently.
1. I like to be doing active things. 0 1 2 3
2. I lose things necessary for tasks or activities (e.g., to-do lists, pencils, books, or
tools). 0 1 2 3
3. I don’t plan ahead. 0 1 2 3
4. I blurt out things. 0 1 2 3
5. I am a risk-taker or daredevil. 0 1 2 3
6. I get down on myself. 0 1 2 3
7. I don’t finish what I start. 0 1 2 3
8. I am easily frustrated. 0 1 2 3
9. I talk too much. 0 1 2 3
10. I am always on the go, as if driven by a motor. 0 1 2 3
11. I’m disorganized. 0 1 2 3
12. I say things without thinking. 0 1 2 3
13. It’s hard for me to stay in one place very long. 0 1 2 3
14. I have trouble doing leisure activities quietly. 0 1 2 3
15. I’m not sure of myself. 0 1 2 3
16. It’s hard for me to keep track of several things at once. 0 1 2 3
17. I’m always moving even when I should be still. 0 1 2 3
18. I forget to remember things. 0 1 2 3
19. I have a short fuse/hot temper. 0 1 2 3
20. I’m bored easily. 0 1 2 3
21. I leave my seat when I am not supposed to. 0 1 2 3
22. I have trouble waiting in line or taking turns with others. 0 1 2 3
23. I still throw tantrums. 0 1 2 3
24. I have trouble keeping my attention focused when working. 0 1 2 3
25. I seek out fast paced, exciting activities. 0 1 2 3
26. I avoid new challenges because I lack faith in my abilities. 0 1 2 3
27. I feel restless inside even if I am siting still. 0 1 2 3
28. Things I hear or see distract me from what I’m doing. 0 1 2 3
29. I am forgetful in my daily activities. 0 1 2 3
30. Many things set me off easily. 0 1 2 3
31. I dislike quiet, introspective activities. 0 1 2 3
32. I lose things that I need. 0 1 2 3
33. I have trouble listening to what other people are saying. 0 1 2 3
34. I am an underachiever. 0 1 2 3
35. I interrupt others when talking. 0 1 2 3
36. I change plans/jobs in midstream. 0 1 2 3
37. I act okay on the outside, but inside I’m unsure of myself. 0 1 2 3
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38. I am always on the go. 0 1 2 3
39. I make comments/remarks that I wish I could take back. 0 1 2 3
40. I can’t get things done unless there’s an absolute deadline. 0 1 2 3
41. I fidget (with my hands or feet) or squirm in my seat. 0 1 2 3
42. I make careless mistakes or have trouble paying close attention to detail. 0 1 2 3
43. I step on people’s toes without meaning to. 0 1 2 3
44. I have trouble getting started on a task. 0 1 2 3
45. I intrude on others’ activities. 0 1 2 3
46. It takes a great deal of effort for me to sit still. 0 1 2 3
47. My moods are unpredictable. 0 1 2 3
48. I don’t like homework or job activities where I have to think a lot. 0 1 2 3
49. I’m absent-minded in daily activities. 0 1 2 3
50. I am restless or overactive. 0 1 2 3
51. I depend on others to keep my life in order and attend to the details. 0 1 2 3
52. I annoy other people without meaning to. 0 1 2 3
53. Sometimes my attention narrows so much that I’m oblivious to everything else;
other times it’s so broad that everything distracts me. 0 1 2 3
54. I tend to squirm or fidget. 0 1 2 3
55. I can’t keep my mind on something unless it’s really interesting. 0 1 2 3
56. I wish I had greater confidence in my abilities. 0 1 2 3
57. I can’t sit still for very long. 0 1 2 3
58. I give answers to questions before the questions have been completed. 0 1 2 3
59. I like to be up and on the go rather than being in one place. 0 1 2 3
60. I have trouble finishing job tasks or schoolwork. 0 1 2 3
61. I am irritable. 0 1 2 3
62. I interrupt others when they are working or playing. 0 1 2 3
63. My past failures make it hard for me to believe in myself. 0 1 2 3
64. I am distracted when things are going on around me. 0 1 2 3
65. I have problems organizing my tasks and activities. 0 1 2 3
66. I misjudge how long it takes to do something or go somewhere. 0 1 2 3
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Appendix H
BRIEF-A: Behavior Rating Inventory of Executive Function- Adult Version Self Report
Form
Instructions: On the following pages is a list of statements. We would like to know if you
have had problems with these behaviors over the past month. Please answer all the items
the best thay you can. Please DO NOT SKIP ANY ITEMS. Indicate your response by
circling
N
if the behavior is
Never a problem
S
if the behavior is
Sometimes a problem
O
if the behavior is
Often a problem.
During the past month, how often has each of the following behaviors been a problem?
N = Never
S = Sometimes
O = Often
1. I have angry outbursts N S O
2. I make careless errors when completing tasks N S O
3. I am disorganized N S O
4. I have trouble concentrating on tasks (such as chores, reading, or work) N S O
5. I tap my fingers or bounce my legs N S O
6. I need to be reminded to begin a task even when I am willing N S O
7. I have a messy closet N S O
8. I have trouble changing from one activity or task to another N S O
9. I get overwhelmed by large tasks N S O
10. I forget my name N S O
11. I have trouble with jobs or tasks that have more than one step N S O
12. I overreact emotionally N S O
13. I don’t notice when I cause others to get mad until it is too late N S O
14. I have trouble getting ready for the day N S O
15. I have trouble prioritizing activities N S O
16. I have trouble sitting still N S O
17. I forget what I am doing in the middle of things N S O
18. I don’t check my work for mistakes N S O
19. I have emotional outbursts for little reason N S O
20. I lie around the house a lot N S O
21. I start tasks (such as cooking, projects) without the right materials N S O
22. I have trouble accepting different ways to solve problems with work, friends, or
tasks N S O
23. I talk at the wrong time N S O
24. I misjudge how difficult or easy tasks will be N S O
25. I have problems getting started on my own N S O
26. I have trouble staying on the same topic when talking N S O
27. I get tired N S O
28. I react more emotionally to situations than my friends N S O
29. I have problems waiting my turn N S O
30. People say that I am disorganized N S O
31. I lose things (such as keys, money, wallet, homework, etc.) N S O
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32. I have trouble thinking of a different way to solve a problem when stuck N S O
33. I overreact to small problems N S O
34. I don’t plan ahead for future activities N S O
35. I have a short attention span N S O
36. I make inappropriate sexual comments N S O
37. When people seem upset with me, I don’t understand why N S O
38. I have trouble counting to three N S O
39. I have unrealistic goals N S O
40. I leave the bathroom a mess N S O
41. I make careless mistakes N S O
42. I get emotionally upset easily N S O
43. I make decisions that get me into trouble (legally, financially, socially) N S O
44. I am bothered by having to deal with changes N S O
45. I have difficulty getting excited about things N S O
46. I forget instructions easily N S O
47. I have good ideas but cannot get them on paper N S O
48. I make mistakes N S O
49. I have trouble getting started on tasks N S O
50. I say things without thinking N S O
51. My anger is intense but ends quickly N S O
52. I have trouble finishing tasks (such as chores, work) N S O
53. I start things at the last minute (such as assignments, chores, tasks) N S O
54. I have difficulty finishing a task on my own N S O
55. People say that I am easily distracted N S O
56. I have trouble remembering things, even for a few minutes (such as directions,
phone numbers) N S O
57. People say that I am too emotional N S O
58. I rush through things N S O
59. I get annoyed N S O
60. I leave my room or home a mess N S O
61. I get disturbed by unexpected changes in my daily routine N S O
62. I have trouble coming up with ideas for what to do in my free time N S O
63. I don’t plan ahead for tasks N S O
64. People say that I don’t think before acting N S O
65. I have trouble finding things in my room, closet, or desk N S O
66. I have problems organizing activities N S O
67. After having a problem, I don’t get over it easily N S O
68. I have trouble doing more than one thing at a time N S O
69. My mood changes frequently N S O
70. I don’t think about consequences before doing something N S O
71. I have trouble organizing work N S O
72. I get upset quickly or easily over little things N S O
73. I am impulsive N S O
74. I don’t pick up after myself N S O
75. I have problems completing my work N S O
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